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For several years, the inability to replace the lost myocardium has been 
studied intensively to define the mechanisms that restrict the regenerative 
capability of the adult heart. Multiple evidence have pointed out that the 
turnover of postnatal mammalian cardiomyocytes is affected by different 
crucial pathways. However, a thorough understanding of the intrinsic 
molecular mechanisms that regulate this process is still far from being 
complete. 

It has been more than a decade since various laboratories initialised the 
study of ubiquitination processes in the heart, reaching the unanimous 
conclusion that it plays a critical role in manipulating virtually all heart 
functions. However, there is fragmentary information about the molecular 
function of this system on the regulation of cardiomyocyte proliferation and 
even less on how this could be exploited for therapeutic purposes. Hence, 
expanding our knowledge on the ubiquitination might devise new strategies 
for cardiac regeneration.  

In this work, we present the identification of ubiquitination factors that 
are essential for cardiomyocyte replication, which was identified by 
harnessing the High Throughput Screening approach. An RNAi-based 
screening was performed, in which approximately 600 ubiquitination 
factors were silenced individually in primary neonatal cardiomyocytes. After 
that, the top siRNAs inhibiting proliferation were selected and investigated 
further to validate their functions in vitro. The validation identified UBE2G1, 
an E2 conjugation enzyme, as the most effective factor induced 
cardiomyocyte proliferation. The depletion of UBE2G1 not only suppressed 
cell cycle progression but also stimulated hypertrophy and counteracted 
the effects of pro-proliferative miRNAs. Administration of AAV9-UBE2G1 in 
neonatal mice promoted the cycling of cardiomyocytes while it preserved 
the heart function in adult mice at the early time points after myocardial 
infarction. Activation of GSK-3β, ERK1/2, and STAT3 signalling pathways 
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correlated with UBE2G1 activity, whereas its interacting partners remained 
to be identified. In summary, we have revealed the implicit potential of 





1.1 Cardiovascular diseases 
1.1.1 The demand for cardiovascular disease studies 
Cardiovascular diseases (CVDs) have been placed as the top cause of 
death worldwide, accounting for over 30% of all deaths, with a total of 
422.7 million cases globally in 2015 (Roth et al. 2017). A few decades ago, 
we observed a phenomenal decline of CVD mortality in nearly all regions, 
with the massive reduction reached 70% in the Netherland (Mensah et al. 
2017). Achievements eased our concerns and rapid progress of treatment 
and prevention that anticipated the control of CVDs mortality. Suddenly, we 
observe a gradual acceleration of CVDs death cases in both genders 
throughout the world (Lopez and Adair 2019). This information indicates 
much works remain to be done in treating heart disease before reaching 
our ultimate goal of reducing its burden.    

Poor prognosis remains a prominent characteristic of CVDs. After 35 
years of medicine development, we have raised 10-year survival of heart 
failure (HF) patients from 20% to 26.2%, and minimal progress was gained 
in treating the end-stage outcome (Mahmood et al. 2014; Taylor et al. 
2019). In terms of CVD epidemiology, its utility was questioned in previous 
periods and even more recently (Vasan and Benjamin 2016). Approximately 
15-20% of myocardial infarction (MI) patients had none of the classical risk 
factors, while more than 50% of HF patients showed average ejection 
fraction (EF) at the time of diagnosis (Ruwanpathirana et al. 2015). For 70 
years of studying, the Framingham Heart Study provides excellent insights 
into the risk factor classification and genetic contribution to heart disease 
development although leaving behind mysterious targets for treatment 
therapy (Andersson et al. 2019). The variances of populations and lifestyle 
factors make it more complications to predict and intervene beforehand. 
Therefore, the cutting edges of biomedical research are desired more than 
ever to propel the future of medicine. We are waiting for the leap of 
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cardiovascular medicine through the rapid advances of big data and 
functional omics to overcome the current challenges.    

1.1.2 Mechanisms of heart development 
Heart development has been studied intensively over a few last decades 
to better understand the molecular mechanisms driving this process. And 
this direction is considered as a central cornerstone to navigate treatment 
therapy. Besides the solid knowledge of foetal cardiomyocyte specification 
and the basic findings in the neonatal and adult heart, we still lack much 
information about the postnatal development of cardiomyocytes. To 
regenerate efficiently the heart after cardiac injuries, replacing 
cardiomyocytes must undergo the exquisite maturation to functional 
synchronisation with pre-existing myocardium. Thus, we will discuss the 




Figure 1.1: Representative cellular events during cardiomyocyte maturation 
(Galdos et al. 2017). The maturation process starts early at the embryonic stage 
and continues at the postnatal stage with modifications in gene expression, cell 
cycling, cardiomyocyte structural arrangement, metabolism switching and the 




Myofibrils. Cardiac myocytes underwent drastic modifications of the 
morphology during the development. Early after birth, mitosis quiescence 
arises, and the cells grow massively in volume. The cell dimension extents 
10-20 times, and they become rod-shaped with specific ultrastructures 
(Mollova et al. 2013; Scuderi and Butcher 2017). Cardiomyocyte 
ultrastructure consists of adjacent myofibril subunits, which serve as the 
contractile apparatus. During the maturation, several myofibrillar proteins 
switch their isoform expressions such as titin (TTN-N2BA to TTN-N2B), 
myosin (MYH6 to MYH7 in human, MYL7 to MYL2), and troponin (TNNI1 to 
TNNI3). Compared with the foetal stage, these modifications result in better 
alignment of the myofibrillar structure while enhancing the membrane 
capacitance following the enlargement of cell surface area. These changes 
also provide a greater velocity of signal electrical transmission and increase 
the contraction force (Spach et al. 2004; Wiegerinck et al. 2009). However, 
the actual molecular mechanisms driving this process remain elusive.       

Electrophysiology. Cardiomyocyte synchronous beating is controlled 
tightly by electrical impulses and oscillations. Briefly, sodium and calcium 
channels depolarise the cells, outward potassium channels repolarise 
portions of the membrane, calcium ion travels inward to excite the 
contraction while potassium ion is pumped outward to drive the membrane 
resting, and the inward rectifying potassium channels maintain the resting 
phase (van den Heuvel et al. 2014; Liu et al. 2016a). Since multiple ion 
channels participate in this reaction, the electrophysiological machinery 
evolves progressively through different heart development stages. 
Cariomyocyte maturation correlates with an increase of ventricular channel 
and a decrease of automated channel presence (KCNJ2 and HCN4, 
respectively); adult myocytes exhibit low automaticity until triggered by 
neighboring cells, with less resting membrane potential, and longer action 
potential duration (Buchanan Jr et al. 1985; Liu et al. 2016a). The 
intercalated disc is a unique feature of cardiac cell-cell connections, which 
forms shortly after birth and involves the assembly of various cell adhesion 
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molecules to allow rapid electrical propagation (Noorman et al. 2009; Vermij 
et al. 2017).

Calcium handling. Calcium ion plays a prominent role in regulating 
cardiomyocyte gene expression, differentiation, and development (Louch et 
al. 2015). Cardiomyocyte maturation correlates with increased significantly 
the expression of Ca2+ handling molecules such as ryanodine receptors 
(RyRs) and sarcoplasmic-endoplasmic reticulum calcium ATPase 2a 
(SERCA2a) (Ruan et al. 2016; Huang et al. 2020). The structural 
components show the gradual loss of T-type channels, whereas T-tubules 
containing L-type channels develop postnatally (Louch et al. 2006). These 
modifications accelerate Ca2+ signalling dynamics to compensate for the 
relatively low Ca2+ intracellular concentration. Of note, around 30% of total 
heart energy is dedicated to Ca2+ trafficking, and thus the effective 
regulation of the flux assists heart function (Smith and Eisner 2019). The 
defects in Ca2+ handling and embryonic reversal of its compartments are 
commonly observed in heart failure and many kinds of heart diseases 
(Gomez et al. 2001; Lenaerts et al. 2009).           
Metabolism. To meet the high demand for energy of the postnatal heart, 
cardiac myocytes progressively switch from glycolysis to oxidative 
metabolism. This metabolic shift was connected to the induction of the 
Peroxisome Proliferator Activated Receptor α (PPARα) and its co-activator 
PGC-1α in several studies (Guo and Pu 2020). In parallel, the upregulation 
of genes encoding oxidative metabolism components and downregulation 
of glycolytic genes were also observed (Uosaki et al. 2015; Malandraki-
Miller et al. 2018). Nevertheless, the actual mechanisms regulating this 
transition are mostly unknown. Notably, mitochondria appear to play a 
crucial role in this process. Mature mitochondria contain dense cristae, the 
folding layer of the inner membrane, which elevates cellular respiration 
capacity. They also grow in size, number, reshape to oval and occupy at 
least 30% of the cell volume eventually (Piquereau et al. 2013; Scuderi and 
Butcher 2017). Mitochondria are distributed along the myofibrils to support 
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the contraction and ion exchange. Dysfunction of mitochondria not only 
results in energy deprivation but is also linked directly to cardiomyocyte 
damage, promoting heart failure progression or dilated cardiomyopathy 
(Brown et al. 2017a; Zhao et al. 2019). 

Cell cycle. The heart undergoes cell cycle quiescence after one week in 
mice and slowly in the first year of humans postnatally. The decrease of 
cyclins and cyclin-dependent kinases (CDKs) expression after birth have 
been reported in many studies, concurrently with increased expression of 
CDK inhibitors (CKIs) during development (Tzahor and Poss 2017; Hashmi 
and Ahmad 2019). Mature cardiomyocytes of most mammalian species are 
multinucleated. Mouse, rat and rabbit have binucleated hearts while the 
multinucleation predominates in porcine hearts (Beinlich et al. 1995; 
Bensley et al. 2016). The distribution of the binucleated cell population was 
highlighted, by which roughly 80% of ventricular cardiomyocytes were 
binucleated in contrast with 14% of atrial myocytes in adult mouse heart 
(Raulf et al. 2015). Human adult cardiomyocytes are mostly mononuclear 
but polyploid due to insufficient karyokinesis was noted from the second 
decade of life (Mollova et al. 2013; Bergmann et al. 2015). Hypertension 
was reported to trigger cardiomyocyte ploidy, and a similar observation 
was noticed in the infarcted heart (Vliegen et al. 1995; Meckert et al. 2005). 
Polyploidisation has been associated negatively with heart regeneration, 
although its actual role remains enigmatic. Uncommon speculation 
suggests that DNA damage could be dodged through this process to 
prevent apoptosis (Gan et al. 2019; Derks and Bergmann 2020). 

Together, understanding cardiomyocyte natural development processes 
will provide valuable insights that could be the source of action towards 
heart regeneration therapy.         
1.1.3 Cardiac treatment strategies 
Despite enthusiasm and efforts in many heart disease treatment trials, 
we are still seeking an effective strategy to regenerate sufficiently human 
heart after the injury (Hashimoto et al. 2018). Transplantation remains the 
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sole solution once patients develop end-stage failure. However, the 
demand for transplantation is met by 10%, due to the lack of donors 
worldwide and the surgical complexity (Trulock et al. 2007; White et al. 
2018).

Myocardial injury is followed by sequential cellular processes to preserve 
heart function. In brief, an acute inflammatory response promotes immune 
cell infiltration to remove the wound of tissue debris, followed by 
myofibroblast proliferation, extracellular matrix deposition, and scar 
formation (Liehn et al. 2011; Prabhu and Frangogiannis 2016). The loss of 
tissue and the scar formation promote adverse left ventricular remodelling, 




Figure 1.2: Current approaches for heart regeneration (Grigorian Shamagian 
et al. 2019). These include transplantation of cardiomyocytes generated from 
different sources (embryonic cells, iPS cells, transdifferentiation from fibroblasts), the 
delivery of various stimulators that enhance the endogenous regenerative capacity or 
the engraftment of engineered muscle tissue to support and promote the recovery of 
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the heart.        

Heart regeneration might be accomplished through numerous strategies, 
mainly centralised in these directions: transplantation of pluripotent cell-
derived cardiomyocytes, direct reprogramming of non-myocytes to cardiac 
fate, or stimulation of the innate proliferative capacity of cardiomyocytes 
(Hashimoto et al. 2018; Sadek and Olson 2020). 

1.1.3.1 Cell-based therapies (transplantation) 
Mesenchymal stromal cells (MSCs). Transplantation of MSCs seemed to 
hold a tremendous promise for heart regeneration among diverse bone 
marrow-derived cells (Hare et al. 2012; Menasché 2018). The benefits of 
using MSCs as a replacement source counts on their low immunogenicity 
and strong paracrine effects compared with other cell types resided in the 
myocardium. They were reported to transdifferentiate into cardiomyocyte in 
vivo at acceptable low rates (Toma et al. 2002; Eschenhagen et al. 2017). 
Although the ultimate cell fate remained controversial and outcomes of the 
clinical trial were variable, MSCs transplantation was shown to be safe 
(White et al. 2016; Pandey et al. 2017). The induction of survival factors, 
angiogenic factors, or growth factors expressed by MSCs might be applied 
to enhance its therapeutic potency, but the evidence of transdifferentiation 
of these cells into cardiomyocytes remains scant at best.

Cardiac stem cells (CSCs). Most studies have focused on the cell 
population expressing C-kit or Sca1 in the heart since they were reported 
to eventually display cardiomyocyte markers in specific conditions in vitro 
as well as in vivo (Zaruba et al. 2010; Jesty et al. 2012). However, several of 
these research have later been challenged, and the actual therapeutic 
benefit of these cells is now heavily questioned by the scientific community 
(Van Berlo et al. 2014; Elhelaly et al. 2019). 

Embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs)-
derived cardiomyocytes. Noticeable results underline the feasibility of these 
cells engrafted in the heart of small and large animals, including primates 
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(Lalit et al. 2014; Shiba et al. 2016; Liu et al. 2018). The efficiency of ex vivo 
differentiation of ESCs or iPSCs to immature cardiomyocytes was reported 
to exceed 80% (Cao et al. 2013; Burridge et al. 2014). Despite their origin, 
these cardiomyocytes were able to couple with the host myocardium 
electromechanical circuit, although arrhythmias were observed in the few 
treated primates. However, the fact that they are allogeneic needs to be 
underlined, thus requiring the immunosuppression of recipients and bearing 
the risk of teratoma formation arising from undifferentiated cells resisting 
the differentiation process (Nussbaum et al. 2007).   

In summary, we are still searching for any effective cell-based therapy for 
the treatment of cardiovascular diseases. Although the improvements of 
cardiac function from research findings or small-scale trials in the past 
decade have elicited great excitement, the actual contribution of cell-based 
therapy still requires the clarification of the molecular mechanisms involved.  

1.1.3.2 Direct reprogramming 
The concept of reprogramming one cell type to another has unlocked a 
fascinating opportunity for regenerative medicine. The discovery from stem 
cell studies has inspired the idea of rebuilding the heart by reprogramming 
cardiac fibroblasts, which constitute roughly 60% of all heart cells, into 
cardiomyocytes and therefore bypassing the risk of tumorigenesis and 
diminish the fibrosis (Xin et al. 2013; Gourdie et al. 2016). An initial 
demonstration of this concept was reported by the identification of a GMT 
cocktail including three cardiac transcription factors GATA4, MEF2c, and 
TBX5, which was shown to stimulate partial transdifferentiation of cultured 
murine fibroblast into cardiomyocyte-like cells (Ieda et al. 2010). Later, the 
GMT cocktail was supplemented by the fourth factor HAND2 (GHMT 
cocktail) to increase the reprogramming efficacy up to ~20% (Song et al. 
2012). 

The following studies have focussed on enhancing the reliability, safety, 
and effectiveness of this process. Efforts were made for stoichiometry 
factors selection of the cocktail, development of appropriate methods to 
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deliver factors of interest or searching for specific cardiac cell subsets 
(Wang et al. 2015b; Miyamoto et al. 2018). Several pathways were 
manipulated to improve the transdifferentiation ratio. These included TGFβ, 
AKT1, WNT, and Notch1 signalling (Ifkovits et al. 2014; Zhou et al. 2015; 
Gourdie et al. 2016). In vivo delivery of GMT or GHMT cocktails by 
retroviruses were shown to reprogram directly cardiac fibroblasts activated 
after myocardial injury (Qian et al. 2012; Song et al. 2012). Besides, the 
introduction of several miRNAs also enhanced reprogramming 
effectiveness in vivo; these included miRNA-1, miRNA-133, miRNA-208, 
and miRNA-409 (Nam et al. 2013; Jayawardena et al. 2015). 

 
Figure 1.3: Several miRNAs are involved in heart regeneration. miRNAs have 
been used to promote cardiomyocyte proliferation, enhancing the differentiation 
and survival of transplanted cells or reducing the adverse effects of non-myocyte 
cells in the heart (Zhu et al. 2016).

Of note, human fibroblasts are more refractory to transdifferentiation, as the 
administration of the indicated cocktails required the aids of MESP1, 
ESRRγ, or myocardin to function (Islas et al. 2012; Fu et al. 2013). A virus-
free method, using combinatorial treatments of the pluripotent gene 
cocktails and nine different chemicals, was reported to efficiently enhance 
human fibroblast transdifferentiation into cardiomyocytes, which eventually 
displayed spontaneously beating (Cao et al. 2016). Despite the variability of 
cardiac reprogramming efficiency, the TGFβ and WNT signalling pathways 
were confirmed to share similar roles in mouse and human cells, thus 
underlined their crucial contributions to this process (Liu et al. 2016b; 
Mohamed et al. 2017). Although the concept of reprogramming seems 
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exciting, several obstacles remain to be addressed before its application in 
heart regeneration. We need to clarify epigenetic modifications that occur 
during the development to set the right stage of transdifferentiated 
myocytes compared with the pre-existing tissue. At the same time, the 
longevity of newborn cells requests verification in vivo. 

1.1.3.3 Stimulation of the innate cardiac regenerative capacity 
Cumulative evidence indicates that cardiomyocytes slowly replicate from 
0.5% to 2% per year in intact adult human and murine hearts (Laflamme 
and Murry 2011; Eschenhagen et al. 2017). Therefore, natural renewal is 
inefficient and incapable of recovering the injured heart but serves as a 
precious regenerative source. Stimulation of endogenous cardiac myocyte 
proliferation has been considered as one of the major paths in cardiac 
regenerative therapy (Singh et al. 2018; Heallen et al. 2019). Hence, 
multiple factors inducing cardiomyocyte turnover have been delivered to 
the heart using different modalities, including protein-coding viral or non-
viral vectors, small RNAs, and small molecules (Grigorian Shamagian et al. 
2019).

Gene therapy. Many attempts were made to understand the molecular 
mechanisms behind the cardiomyocyte cell division. Various factors, cell 
cycle regulators, and intrinsic signalling pathways were identified to play 
the crucial roles in cardiogenesis, cardiomyocyte maturation, and 
epigenetic modifications. The evolution of vectors and delivery systems has 
provided researchers powerful weapons to intervene in particular genes or 
pathways of interest (Wolfram and Donahue 2013). Early efforts were made 
by Dr. J. Isner and colleagues to inject intramuscular naked plasmid 
encoding VEGF that could augment collateral development and tissue 
perfusion (Tsurumi et al. 1996). As a non-integrative approach, plasmid 
DNA delivery is straightforward and avoidable the risk of tumorigenicity. 
However, it failed to convince functional improvement was significant 
through several trials and the transgene expression was simply low (Vale et 
al. 2000; Mendiz et al. 2011). Afterwards, viral vectors were viewed as an 
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effective method to deliver target genes to the heart. Lentiviral, adenoviral, 
and adeno-associated virus-based vectors are the most common viral 
vectors currently used. Multiple genes were introduced to the heart using 
viral vectors to stimulate endogenous cardiomyocyte proliferation. The 
combinatorial delivery of vector expressing cell cycle regulators including 
CDK1/CCNB/CDK4/CCND increased significantly the rate at which adult 
cardiomyocytes underwent cell division (Mohamed et al. 2018). Studies in 
rat and pig models for the overexpression of cyclin A2 mediated by an 
adenoviral vector protected the infarcted heart and induced cardiac 
regeneration (Woo et al. 2006; Heallen et al. 2019). Along the same 
concept, AAV9 expressing Salvador shRNA was injected in the infarcted 
heart to modulate Hippo pathway activity and improve heart function 
(Leach et al. 2017). The rise of CRISPR/Cas9 technology provides a 
powerful tool for the field of genome editing, which has been explored to 
correct the mutation of some essential genes in the heart. Several attempts 
were made to deliver CRISPR/Cas9 components to correct Myh7 and 
Mybpc3 mutations in hypertrophic cardiomyopathy (Cannatà et al. 2020). 
Moreover, CRISPR/Cas9 mediating Mybpc3 correction was achieved at 
high yield in human preimplantation embryos (Ma et al. 2017). 

Extracellular vesicles. These are a heterogeneous group of cellular 
particles comprising two major classes: exosomes and microvesicles. The 
exosome is derived from a multivesicular endosome fused with the cell 
membrane, while the microvesicle is a highly variable class regarding their 
origin and secretion process (De Jong et al. 2014; de Abreu et al. 2020). An 
extracellular vesicle can comprise many forms of RNA (mRNAs, miRNAs, 
non-coding RNAs), DNA, lipids, or proteins (Valadi et al. 2007; O’Brien et al. 
2020). Recent evidence supports their roles in vascular homeostasis, 
cardiac fibrosis, or cardiac pathological progression (Bang et al. 2014; 
Beltrami et al. 2017). Exosomes from the cultured human cardiosphere-
derived cell (CDC) were shown to promote cardiomyocyte proliferation and 
inhibit apoptosis. These exosomes were able to preserve the heart function 
and structure after 42 days from myocardial infarction by upregulating 
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miR-146a expression (Gallet et al. 2016). In another study on cardiac 
progenitor cells (CPCs), extracellular vesicles derived from CPCs released 
several miRNAs such as miR-210, miR-132, and miR-146a-3p, to suppress 
apoptosis in cultured cardiac cells and maintain the cardiac function of 
infarcted mice (Barile et al. 2014). Interestingly, current reports suggest that 
extracellular vesicles can deliver full mitochondrial genomes to recipient 
cells, subsequently recovering their respiratory activity and enhancing cell 
survival (Sansone et al. 2017; Puhm et al. 2019).  

MicroRNAs (miRNAs) and Long non-coding RNAs (lncRNAs). miRNAs 
have been studied extensively since their discovery in the early 1990s by 
Victor Ambros and colleagues (Lee et al. 1993). MiRNAs are described as 
small regulatory RNAs that modulate gene expression at the post-
transcriptional level by pairing with complement mRNA at target sequences 
(Thum et al. 2007; Small and Olson 2011; Hashimoto et al. 2018). miRNAs 
are transcribed and processed from specific genes located within introns or 
exons of coding genes (Ha and Kim 2014); transcription starts from the 
hosting promoter or from self-promoters (MacFarlane and R Murphy 2010). 
Expression of miRNAs can be regulated by miRNA gene modification, RNA 
editing or methylation (Misiewicz-Krzeminska et al. 2019). The most 
common function of miRNAs is to reduce gene expression, by which 
sufficient matching to target mRNAs leads to their degradation while partial 
matching mostly inhibits their translation (Bartel 2004). miRNAs regulate 
many biological processes, including cardiogenesis and development of 
cardiovascular disease. One of the early reports about miRNAs controlling 
cardiomyocyte proliferation was the identification of the miR-15 family, 
which regulates postnatal mitotic arrest (Porrello et al. 2011). Furthermore, 
our group has provided striking evidence that miR-199a-3p and 
miR-590-3p are able to induce proliferation of postnatal and adult 
cardiomyocytes (Eulalio et al. 2012). Advances in delivery methods showed 
that the administration of a miRNA-302 hydrogel improved local 
cardiomyocyte proliferation and increased the number of myocytes in adult 
mouse heart (Wang et al. 2017). The crosstalk between ubiquitination and 
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miRNAs we reported recently, when infarcted CD57 mice injected with 
miRNA-1 that the function of the proteasome was associated with miRNA 
expression (Wei et al. 2019). Although most therapeutic miRNAs for cardiac 
regeneration are still in preclinical developing stages, a few miRNAs have 
reached clinical trials for other applications (Janssen et al. 2013; Beg et al. 
2017). In particular, MRG110 (a synthetic miRNA-92 inhibitor) is one of the 
few ongoing trials for heart failure treatment (Hanna et al. 2019). 

Figure 1.4: miRNA maturation process. The pri-miRNA is transcribed from 
miRNA gene or intron and then cleaved by the Drosha-DGCR8 complex in the 
nucleus to create the pre-miRNA. After expor to the cytoplasm, pre-miRNA is 
processed further by Dicer-TRBP to form miRNA duplex. Ago2 loads miRNA 





Besides miRNAs, the transcriptional activity of the mammalian genome 
mainly results in the generation of non-coding RNAs (Kashi et al. 2016). In 
particular, long non-coding RNAs (lncRNAs) are a heterogeneous class of 
RNA transcripts of over 200 nucleotides comprising sense, antisense, 
intronic, bidirectional, intergenic and enhancer subclasses (Abbas et al. 
2020; Tang et al. 2020). Over the last few years, mounting evidence have 
indicated that lncRNAs interact with DNA, mRNA, and even miRNAs to 
controlthe splicing, transcriptional or post-translational modification of the 
factors involved in various cellular function (Kuo et al. 2019; Kazimierczyk 
et al. 2020). LncRNAs are connected with ubiquitination to regulate the 
proteolysis, as in the case of lncRNA-CCDST promoting binding of E3 
ligase MDM2 with the substrate DHX9 in cervical cancer (Ding et al. 2019). 
As far as cardiomyocyte proliferation is concerned, this process is also 
under the control of different lncRNAs. For example, the upregulation of 
lncRNA ECRAR promoted cytokinesis of postnatal and adult cardiac 
myocytes by activating the ERK1/2 pathway (Chen et al. 2019). The Sirt1 
antisense lncRNA overexpression in vitro was reported to induce mitosis 
while improving adult mice survival and heart function after infarction (Li et 
al. 2018). 

Small molecules: It is estimated that roughly 40% of the cell volume is 
occupied by large biopolymers such as DNA, RNA, proteins, and other 
macromolecules. Besides, the cells also contain small molecules, which are 
a heterogeneous group of low molecular weight molecules such as lipids, 
sugars, drugs, and other xenobiotics (Gerry and Schreiber 2020). This 
group of molecules can interfere with multiple biological processes, 
including cell signalling, membrane trafficking, DNA replication, and 
epigenetic modifications (Cañeque et al. 2018). In terms of administration, 
small molecules are preferably compared to nucleic acids or proteins to 
treat cardiac disease since they can be delivered orally and uptaken 
directly by the body (Petrone and DeFrancesco 2018). A major issue is 
identifying suitable small molecules for cardiac regeneration, which is a 
challenging proposition given by the complexity of the biological pathways 
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regulating endogenous cardiomyocyte proliferation. A few small molecules 
have been described to enhance cardiomyocyte proliferation and hold a 
promising potential for cardiac regeneration. For example, from a large 
scale screening of around ~147.000 small molecules targeting the Nkx2.5 
gene, Schneider and colleagues reported the discovery of sulphonyl-
hydrazone (Shz), which was able to induce cardiac cell fate of adult 
progenitor cells (Sadek et al. 2008). More recently, a novel compound 
(TT-10) derived from the fluorination of TAZ-12 was reported to increase 
cardiomyocyte proliferation in vitro as well as decrease cardiac remodelling 
in adult mice after MI through its anti-apoptotic effects (Hara et al. 2018). 

1.1.4 The complexity of cardiac regeneration 
Regeneration is commonly defined as the process by which lost or 
damaged tissue is replaced by new tissue. Although most of the works so 
far conducted has aimed at the creation of new cardiomyocytes since they 
are the main functional population in the heart, we have to remember that 
the myocardium also comprises other cell types, which collectively account 
for more than 60% of the cells in an adult heart. Thus, the induction of 
cardiomyocyte proliferation is crucial but merely not enough to reconstitute 
the injured tissue. In broader terms, trauma can be found at different levels 
of the heart: cellular death, tissue architecture disruption, lack of proper 
vascularisation, impaired interaction with white blood cells (Grigorian 
Shamagian et al. 2019). Consequently, an ideal scenario is to rebuild the 
heart based on the orchestrations of multiple actions: remuscularization, 
electromechanical coupling, and the modulation of inflammatory and 
immune response (Bertero and Murry 2018; Cao and Poss 2018).

Remuscularization. This term refers to the myocardium restoration with 
new cardiomyocytes and subsequent blood vessel formation and 
connective tissue. In the past, non-myocyte resident cells were viewed as 
spectators during the regenerative process. However, it has become clear 
that these cells form a scaffold to support the newborn myocytes 
organisation and promote their survival (Gray et al. 2018). Moreover, recent 
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information concludes that regenerative programs are set as different gene 
expression profiles in all the cardiac cell types (Goldman and Poss 2020). 
Therefore, a single intervention on cardiomyocytes for a complex organ like 




Figure 1.5: Heart regeneration properties (Bertero and Murry 2018). Sufficient 
cardiac regeneration requires the regeneration of myocardium by new myocyte, 
blood vessel, and connective tissue that needs to couple with electromechanical 
circuit of existing tissue. Immune response also modulates this process. 

Electromechanical coupling. As we have learned from development 
lessons, reassembly of the heart requires the generation of fully functional 
cardiomyocytes in terms of excitation-contraction machinery composition. 
Aside from finding new sources of cardiomyocyte, tissue synchronisation 
has always been one of the most troubling issues for cardiac regenerative 
medicine (Heallen et al. 2019; Sadek and Olson 2020). In cytological terms, 
this means heart regeneration can only achieve from accomplishing all 
aspects of reconstruction of the transverse tubules, gap junctions, and ion 
channels, besides forming new myofibrils within the newly generated cells. 

Modulation of the inflammatory and immune responses. An adequate 
tissue replacement after a myocardial injury is regulated by immune and 
inflammatory cells. In particular, an appropriate inflammatory response is 
crucial to eliminate necrotic cells, trigger angiogenesis, and fibroblast 
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ingrowth (Liehn et al. 2011; Prabhu and Frangogiannis 2016). However, the 
blunting of this inflammatory response is crucial to start the recovery 
phase. Due to indistinct boundaries between beneficial and harmful 
contributions, inflammatory and immune cells are somehow underrated on 
the heart regeneration path. Excessive reactions may lead to the collateral 
damage of reforming tissue and slow down the healing (Sattler et al. 2017). 
In this respect, a thorough understanding of the actual molecules secreted 
by white cells present in the blood or resident in the myocardium might 
lead to the definition of therapeutic proteins that might improve new 
cardiomyocyte and blood vessel formation to enhance the functional 
outcome of regenerative approaches.

In conclusion, heart regeneration is a daunting task that requires more in 
depth investigation to set up the right stage for multiple cell populations 
and cellular factors building up the functional tissue.   

1.2 The ubiquitination machinery 
In the early days of protein metabolism studies, proteins were defined as 
an everlasting molecule that, once produced, stayed indefinitely with the 
host (Ohsumi 2014; McDowell and Philpott 2016). Later on, this dogma was 
challenged by the observation of proteolysis in vivo. In this experiment, the 
animals were fed with the foods containing labeled atoms and the signal 
was detected in their tissue that indicating some form of protein turnover 
(Bloch and Schoenheimer 1939; Ohsumi 2014). In the 1980s, a milestone of 
ubiquitination study was introduced by Hershko, Ciechanover, Rose, 
Varshavsky with other colleagues for the discovery of this system 
(Ciechanover et al. 1980; Hershko et al. 1980). 

Ubiquitylation is a reversible post-translational modification in which 
ubiquitin(s) are covalently linked with recipient proteins at lysine residue 
through an enzymatic cascade (Callis 2014; McDowell and Philpott 2016). 
This modification occurs in virtually all cellular activities, including cell cycle 
progression, apoptosis, intracellular trafficking, and viral infection (Swatek 
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and Komander 2016). In particular, most intracellular proteins are degraded 
through the ubiquitin-proteasome system, whereas extracellular proteins 
are taken up by endocytosis and degraded via lysosomes (Lecker et al. 
2006). Tightly control of protein turnover is crucial for maintaining the 
proper function of mammalian cells. For example, rapid modifications of 
specific proteins allow host cell adaptation to physiological shifts. This is 
the case of UBI4, an inducible factor of stress response to DNA damage or 
heat shock, which provokes the rapid formation of ubiquitin molecule 
(Gemayel et al. 2017), or of the E3 ligase PIRE, which modulates the ROS 
production to defend from a bacterial infection (Lee et al. 2020).  

The ubiquitination system includes diverse types of factors. In particular, 
there are 2 members of ubiquitin activating enzyme (E1), approximately 40 
members of ubiquitin conjugating enzyme (E2), and over 600 ubiquitin 
ligases (E3) in mammalian cells (Clague et al. 2015). Besides, the genome 
also encodes around 100 deubiquitinating enzymes and accessory chain 
elongation factors called E4 (Koegl et al. 1999; Nielsen and MacGurn 2020).        

1.2.1 General mechanism  
Since the ubiquitination was first identified as a proteolytic pathway, it 
was often associated with the proteasome to be collectively named the 
ubiquitin-proteasome system. However, this nomenclature partially explains 
its function since countless research of ubiquitylation driving non-degraded 
modifications of the substrates published to date testify.

The ubiquitination process starts when ubiquitin is activated by a 
covalent linkage between its C-terminus (glycine 76) and a cysteine residue 
of E1, then activated ubiquitin is transferred to a cysteine residue of E2 
before the E3 mediates its attachment canonically to a lysine residue of a 
substrate protein (Pagan et al. 2013). Depending on the distinct chain 
topology given by the ubiquitination, substrate proteins can have various 
outcomes. For example, the mono-ubiquitylation can alter protein-protein 
interactions, homotypic chain linkage at lysine 11 or 48 primes the receiver 
protein to proteolysis while heterotypic chain addition onto lysine 63 can 
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mediate the endocytosis or protein assembly (Clague et al. 2015; McDowell 
and Philpott 2016). Therefore, the prediction of protein behavior followed 
ubiquitylation requires an intensive analysis of chain formation and its 




Figure 1.6: Ubiquitination and its roles in various cellular processes adapted 
and modified from (Kaiser and Huang 2005). (a) Ubiquitination comprises several 
enzyme types and catalyses ATP-dependent reactions. (b) Polyubiquitylation of 
substrate results in proteolysis. (c) The proteasome degrades ubiquitylated 
substrates and deubiquitinase reuses ubiquitin molecules. (d) Different types of 
modifications drive various substrate outcomes.      

1.2.2 Components   
1.2.2.1 Ubiquitin  
Staying at the heart of the ubiquitylation process is the tiny, 76 amino 
acid-protein ubiquitin, which is highly conserved and expressed universally. 
Across various eukaryotic kingdoms, ubiquitin has changed only a few 
residues between plants, fungi, and animals (Zuin et al. 2014). The 
interchangeable function of ubiquitin was examined by providing ubiquitin 
derived from yeast to plants, and the subsequent results presented no 
significant differences was found in the plant phenotype (Ling et al. 2000). 
This experiment revealed among those that indicated that the ubiquitous 
function of ubiquitin had been maintained along with evolution.

Ubiquitin molecule has a globular structure composed of five β-sheets 
encompassing an ⍺-helix packaged tightly to enhance protein stability and 
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prevent heat denaturation. The C-terminus of ubiquitin is less preserved to 
interact with multiple target proteins (Dikic et al. 2009). In humans, ubiquitin 
protein is encoded by four genes. The UbB and UbC genes encode 
polyubiquitin chain precursors consisting of nine ubiquitin molecules and 
associate with the proteasome for substrate proteolysis. While the UBA52 
and UBA80 genes encode ribosomal subunits comprising a single ubiquitin 




Figure 1.7: Various ubiquitin chain linkages and their functions adapted and 
modified from (Park and Ryu 2014; Buetow and Huang 2016). a. Types of 
ubiquitylated modifications with known functions. b. Ubiquitylation at the residues 
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with unknown function.    

As mentioned before, ubiquitin chains can be conjugated to each other 
through eight internal residues in order to form a variety of chain linkages. 
The residues involved are methionine 1 at the N-terminus and seven lysine 
residues at positions 6, 11, 27, 29, 33, 48, and 63 (Dikic et al. 2009; Winget 
and Mayor 2010). Intriguingly, a significant number of ubiquitin molecules 
are detected as monoubiquitin conjugates in mammalian cells. For 
example, in HEK293 cells, approximately 60% of total ubiquitin chains are 
in the form of monomeric protein (Kaiser et al. 2011). 

Multiple pathways and factors were found to be regulated by ubiquitin-
like proteins in a similar manner (Hoeller et al. 2006). Ubiquitin-like proteins 
share an ⍺-helix and a β-sheet structure analogous to ubiquitin, but they 
principally mediate the interactions of proteins with other macromolecules. 
Moreover, their structures also recall some traits of prokaryotic proteins 
(Hochstrasser 2009). The ubiquitin-like protein modifications include the 
sumoylation (involving the addition of the SUMO polypeptide), neddylation 
(NEDD8), ISGylation (ISG15), and fatylation (FAT10). Additional ubiquitin-like 
proteins are ATG8, ATG12, URM1, and UFM1 (Hoeller et al. 2006; 
Cappadocia and Lima 2017).

1.2.2.2 Ubiquitin activating enzyme (E1) 
The ubiquitylation process is initiated by the ubiquitin activating enzyme 
(E1). In brief, the activation begins when the C-terminus of ubiquitin is 
adenylate by E1 using energy from ATP hydrolysis. This reaction generates 
high energy ubiquitin-AMP self-transferred onto a cysteine residue of E1 
(Callis 2014; McDowell and Philpott 2016). After this step, a thioester bond 
is formed between E1 and the C-terminus of “activated” ubiquitin. This 
binding results in a conformational change exposing a binding site to 
ubiquitin conjugating enzyme (E2) and release AMP (Rape 2018). Generally, 
E1 comprises four domains: a binding domain consisting of two motifs to 
turn “on” and “off” adenylation, a catalytic domain containing the active 
cysteine, an intermediate layer of four helices assisting the binding of E1 
26
Introduction
and ubiquitin, and a C-terminus portion interacting with specific E2s (Lee 
and Schindelin 2008). 

There are two E1s in vertebrates to initiate the process of Ubiquitylation. 
Of these, for several years, UBE1 was believed to be the sole E1. The 
discovery of UBA6 has then added a new layer of complexity (Jin et al. 
2007). UBE1 and UBA6 are unrelated factors, as the overlapping of their 
structures is only approximately 40% (Schulman and Harper 2009). Even 
though both proteins are expressed in various cell types, the UBE1 level is 
far more abundant than that of UBA6. In terms of activity, UBA6 is 
responsible for less than 1% of total ubiquitylation activity, which also 
explains why its existence has escaped the identification for many years 
(Hyer et al. 2018). UBE6 is known to interact uniquely with the USE1 E2 
enzyme.          

1.2.2.3 Ubiquitin conjugating enzyme (E2) 
In the subsequent step of ubiquitylation, the ubiquitin conjugating 
enzyme (E2) continues the cascade by first accepting “activated” ubiquitin 
at a cysteine active site and dissociating from E1. Then, it interacts with 
cognate E3 ligase(s) to recruit the substrate (Ye and Rape 2009). There are 
two main types of reactions carried out by E2s: transthiolation (movement 
of a thiol group between two molecules) and aminolysis (movement of a 
thiol group to an amino group) (Stewart et al. 2016). Approximately 40 E2 
members have been identified in humans. Most of them are small proteins, 
except UBE2O3, the mass of which exceeds 230 kDa. Due to their 
relatively small size, E2s bare a single-core domain for catalysis named 
UBC comprising 140-200 amino acids that is formed by four ⍺-helices and 
one β-sheet (Polge et al. 2015). E2s are classified into four classes 
according to their structures: class I possesses only the core domain, class 
II and III require either N-terminus or C-terminus for catalyzing, while class 
IV contains both of them (Polge et al. 2015; McDowell and Philpott 2016). 

A single E2 can interact with one or multiple E3s, and those interactions 
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can have either weak or moderate strength. Thus, a traditional approach 
based on pulldown assays is not suitable to identify the physiological 
paring of E2-E3 in most cases. A low affinity of the E2-E3 interaction may 
be an advantage for ubiquitin chain formation. As E2 cannot be “used” by 
E1 while E3 is binding, the release of E3 is needed for initialising the 
sequential reaction. The interchange between attachment and detachment 
usually takes time and slows down the turnover of E2. In some conditions, 
accelerating chain formation is achieved through auxiliary site interaction of 
E2-E3 outside the canonical domain (Eletr et al. 2005; Ye and Rape 2009). 
Remarkably, ubiquitin chain topology can be determined alone by E2, as 
several of these proteins are able to synthesize K48 polyubiquitination 




Figure 1.8: Different ubiquitin linkages based on types of interaction between 
E2 and substrates (Stewart et al. 2016). E2 conjugating enzyme transfers 
ubiquitin onto different residues of the substrates. 

In the cells, E2s can play different roles since several of these proteins 
participate in the initiation of the ubiquitin chain, including the UBE2D 
family, while others are more prone to the chain elongation. In the case of 
UEV, it has several variants, which contains the UBC domain but lacks a 
cysteine active site. Instead of directly performing the ubiquitylation, UEVs 
bind other active E2s and act as cofactors in the catalysis (Pickart and 
Eddins 2004). Although the conjugation of activated ubiquitin to an E2 is 
the most common activity in the cells, these proteins also possess a low 
ubiquitin transfer rate in undefined mechanisms. Additionally, some of the 
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E2s have highly equivalent isoforms, for example UBE2A is 96% similar to 
UBE2B (Polge et al. 2015). Therefore, it remains still unclear how such a 
relatively small number of E2s can work in conjunction with a large number 
of E3s in a highly specific manner and whether redundancy exists.   

1.2.2.4 Ubiquitin ligase (E3) 
Ubiquitin ligase (E3) is responsible for the transfer of “activated” ubiquitin 
to substrates. In detail, these factors mediate specifically the recognition of 
target proteins. E3s are the largest family of enzymes in the ubiquitylation 
machinery, with an estimate that the human genome encodes more than 
600 of them (Senft et al. 2018). Generally, all E3s harbour an interacting 
domain with E2, although the structures and their modes of action seem to 
vary. Interestingly, multiple E3s with various structures may facilitate similar 
interactions (McDowell and Philpott 2016). So far, E3s have been classified 
into three major subgroups according to their characteristic domain as well 
as the ubiquitin transfer mechanism (Morreale and Walden 2016). 

RING E3s (Really Interesting New Gene). They are the most abundant 
family since approximately 600 of RING E3s were found in humans 
(Morreale and Walden 2016). A canonical RING domain consists of 30-100 
residues motif coordinated by two zinc ions; the structure of around 340 
RING E3s has been validated. U-box enzyme is a sub-group of RING E3 
proteins that possess a classical domain lacking the zinc coordination part, 
and eight of them have been detected in human cells. Both classical RING 
and U-box E3s catalyse the ubiquitin transfer directly from an E2 to the 
substrate.

RING members can catalyse the reaction as monomers, homodimers 
(the complex of two molecules of a RING ligase), or heterodimers (the 
complex of two different RING ligases). In some particular circumstances, 
they form complexes of multisubunit E3s, such as Cullin-RING ligases or 
APC/C complex. With more than 300 substrate receptors confirmed in 
humans, the Cullin family is responsible for 20% protein degradation 
carried out by proteasome (Clague et al. 2015). Furthermore, RING E3s can 
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Figure 1.9: Numerous types of RING E3 ligases (Morreale and Walden 2016). 
These can be recognised as classical RINGs, U-box, Cullin-RING or multi-
subunit ligases. 

HECT E3s (Homology to E6AP C-Terminus). These were named after the 
discovery of their prototypical domain within the E6-AP protein of human 
cells. Unlike the previous E3s group, HECT E3s perform ubiquitin transfer 
through a two-step reaction: the HECT domain facilitates “activated” 
ubiquitin acceptance from E2, and the binding domain at the N-terminus 
recruits the substrate (McDowell and Philpott 2016). The HECT domain 
comprises 350 amino acids and locates at the C-terminus (Callis 2014; 
Buetow and Huang 2016). In order to interact with E2, two lobes of HECT 
domain work collectively to form a flexible hinge in which the N-terminal 
lobe connects with E2 at one side, and the C-terminal lobe at the other side 
contains an active cysteine to catalyse the transfer (Morreale and Walden 
2016). Substrate specificity is regulated by N-terminal extensions, by which 
these proteins can be divided into three subfamilies. These include NEDD4, 
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HERC, and leftover members. So far, 28 HECT E3s have been identified in 
humans.

RBR E3s (RING-IBR-RING). They are an interesting group of E3 which 
have been discovered recently. Using a hybrid mechanism, RBR E3s 
possess RING domains and implement ubiquitin transfer via a two-step 
reaction. Together, RING1 interacts with E2 and places “activated” ubiquitin 
onto RING2 to proceed with the conjugation of ubiquitin and the substrate 
(McDowell and Philpott 2016). Although sharing the core of catalysis, each 
member of RBR E3s owns an additional domain that is structurally different 
and involves in intramolecular interactions (Callis 2014). Some of these 
domains were reported to arrest the enzyme at an auto-inhibited state that 
allows the rapid catalysis in response to phosphorylation or protein-protein 
interaction (Morreale and Walden 2016). 14 members of RBR E3s have 
been identified in humans. 

Of note, HECT E3s determine the substrate specificity as they receive 
“activated” ubiquitin before transferring it to the substrate, whereas in RING 
E3s catalytic reaction, E2 plays a determining role (Stewart et al. 2016). 

1.2.2.5 Ubiquitin accessory chain elongation factor (E4) 
As mentioned before, polyubiquitin chain linkages are required by 
ubiquitination to drive the degradation of substrates. In a classical manner, 
single ubiquitin moieties are added sequentially to the chain, and this cycle 
is repeated until the completion. Nonetheless, the question of how to 
mediate concurrently the formation of polyubiquitin and branched ubiquitin 
chain is still poorly understood. Relevant to this problem, Manfred and 
colleagues initially identified an accessory elongation factor, called E4. In 
the absence of E4, the formation of the ubiquitin chain was insufficient for 
proteolysis in vivo. E4 was described to promote the pre-assembly of 
polyubiquitin chains, which could be conjugated rapidly to a substrate, thus 
increasing assembly speed (Koegl et al. 1999). After this original report, 
several E4s have been detected in mammalian cells. Bypassing the 
classical cascade, the participation of E4 is an obvious benefit for saving 
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time and energy of proteolysis.     

1.2.2.6 Deubiquitinating enzyme (DUB) 
Besides controlling cellular protein turnover, ubiquitylation also plays a 
master role in the governance of signalling pathways. Similar to other post-
translational modifications, ubiquitylation is reversible and tightly 
supervised by deubiquitinating enzymes (DUBs). DUBs can be attracted to 
particular protein targets based on interacting domains or recognised by 
specific linkage architectures (Clague et al. 2019). The mammalian genome 
encodes around 100 DUBs associating with ubiquitin precursor cleavage 
and recycling of the ubiquitin molecule after the degradation (McDowell 
and Philpott 2016). Recent data also indicate the contribution of these 
enzymes to ubiquitin chain editing (Mennerich et al. 2019). Of note, the 
effects of DUBs on ubiquitin removal correlate with substrate stability as 
well as function. 

Depending on sequence and structure, DUBs are classified into seven 
subgroups (Reyes-Turcu et al. 2009; Clague et al. 2019): USP, UCH, OTU, 
MJD, MINDY, ZUP1, and JAMM. Except for JAMM family members, which 
are zinc-dependent metalloproteases, the remaining DUBs are cysteine-
dependent proteases (Clague et al. 2015). Among them, USP is the largest 
and the most diverse group. Most DUB functions are enigmatic, as these 
proteins contain various structural motifs for catalysis, ubiquitin binding 
and protein interaction domains. Hence, it comes to no surprise that they 
are highly regulated by phosphorylation, ubiquitylation, or sumoylation that 
affects both their activities and localisation (Reyes-Turcu et al. 2009).

1.2.3 Current approaches for studying ubiquitination 
Since the discovery of protein modification by the ubiquitylation process, 
the identifications of specific substrates and types of modification have 
always been the holy grails in this field. Several challenges remain to be 
overcome in this respect, including weak interactions of ubiquitination 
compartment and substrate, the diversity of factors with redundant 
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functions, rapid destruction of target protein, and highly dynamic 
modification in contextual dependent. Many biochemical and bioinformatic 





Figure 1.10: Current approaches to identify E3 ligase substrates (Iconomou 
and Saunders 2016). The identification of substrate can be achieved through 
these approaches: yeast two hybrid, in vitro phage display screening, luminescent 
in vitro ubiquitylation assay, high-throughput quantitative microscopy, global 
protein stability profiling or protein array.      

Biochemical tools. These are the methods of choice when someone 
aims at investigating the ubiquitination. Overall, strategies encompass the 
detection of crucial reactivity sites of E3 ligases including the inhibition of 
DUB releasing ubiquitin molecule from the substrate, the modification of 
binding and transferring mechanism, and the development of novel adaptor 
or tracker proteins (Iconomou and Saunders 2016). For example, the new 
tandem ubiquitin binding entities (TUBEs) can be fused with many ubiquitin 
binding domains to create a “molecular trap” by which can be pulldown 
and analysed by mass spectrometry (Hjerpe et al. 2009; Azkargorta et al. 
2016). A genetic approach, such as ubiquitin activated interaction traps 
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(UBAITs) was also developed recently (Maculins et al. 2016). In addition, the 
orthogonal ubiquitin transfer (OUT) technology has been exploited to profile 
the targets of UBA1 and UBA6 in mammalian cells (Liu et al. 2017). 
Remarkably, the latest imaging advances provide excellent tools to 
visualise and track ubiquitin-related processes in living cells, such as the 
fragment of Kusabira Green fluorescent protein or GFP-based UPS reporter 
(GFPu) (van Wijk et al. 2019).

Bioinformatic tools. Several databases have been developed to supply 
comprehensive resources for ubiquitination research. There are Ubibrowser, 
UUCD, Ubiprot, mUbiSiDa for ubiquitylated proteins in mammals, or 
hUbiquitome, which contains experimentally verified ubiquitylation data in 
human cells. 

1.3 Targeting ubiquitination for treatment therapy  
Ubiquitination is an important therapeutic target for various human 
diseases, including cancer, diabetes, and cardiovascular diseases. Drug 
discovery of this area has achieved significant progress in the last decade 
since bortezomib was the first proteasome inhibitor approved by the FDA 
to treat hematologic malignancies in 2003 after a 7 years of clinical trial 
(Cohen and Tcherpakov 2010). Subsequently, other inhibitors were also 
licensed for treating lymphoma, lung cancer, or pancreatic cancer. The 
potential use of such inhibitors in therapy is relatively high, given the 
numerous linkages between ubiquitination compartments and cellular 
functions. Unfortunately, proteasome inhibitor is an only group of molecules 
associating with the ubiquitination used in clinical treatment (Deng et al. 
2020). 

Several E1 inhibitors were developed but only one entered a clinical trial 
due to the issue of specificity (Kleiger and Mayor 2014; Huang and Dixit 
2016). The development of E2s/E3s inhibitors has lagged although these 
proteins control substrate specificity and modification types. In 2011, the 
first inhibitor of an E2 enzyme (CC0651) was found by targeting human E2 
34
Introduction
UBE2R1 (Ceccarelli et al. 2011; Harper and King 2011). Later, two inhibitors 
of UBE2N were also discovered to block the transfer of ubiquitin to 
substrates. Targeting E3 was rewarded with some success and led to the 
identification of different inhibitors of the E3 ligase MDM2 including MI-63, 
Mel 23 or idasanutlin, which is currently in phase I clinical trial for blood 
cancer patients (Yang et al. 2005; Ding et al. 2006; Mascarenhas et al. 
2019). A group of E3 ligases comprising the Inhibitor of Apoptosis Proteins 
(IAP) is the major target of cancer treatment, as these proteins prevent 
apoptosis and thus allow cancer cell survival. Antagonists of IAP ligase are 
ongoing clinical trials, such as LCL-161, Birinapant, or AT-406 (Scott et al. 




Figure 1.11: Preclinical and clinical trials target ubiquitination components 
(Deng et al. 2020). Many compounds and factors have been investigated to target 
ubiquitination at all levels of the reactive cascade.  

Interestingly, while much of the work is aimed at blocking the active site 
of target proteins, ubiquitylation can be exploited in other directions as well. 
A new set of small molecules call proteolysis targeting chimeras (PROTACs) 
was constructed to target particular substrates and thus accelerate their 
proteolysis in vivo (Bondeson et al. 2015). Traditional inhibitors or activators 
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work through interaction with selective pockets to alter the inner structure 
of target proteins, which leads to unwanted functions in some cases. 
Therefore, PROTACs have considerable advantages in eliminating abnormal 
protein synthesis as usually seen in multiple cancers. This new class of 
degraders has hit clinical trials in 2019 (Mullard 2019).

In the cardiovascular disease scenario, ubiquitination has been studied 
for years and there is no doubt it plays pivotal roles in all heart functions 
(Pagan et al. 2013). Dysfunction of the machinery was detected in many 
heart diseases, which correlates with apoptotic and hypertrophic factor 
accumulation, alteration of cell mass and disruption of sarcomeric structure 
(Hedhli and Depre 2009; Henning and Brundel 2017). For example, muscle 
atrophy F-box (MAFbx) is an E3 that controls the level of calcineurin and its 
subsequent pathway - nuclear factor of activated T cells (NFAT) -, which 
controls the maladaptive remodelling of cardiac tissue (Baskin et al. 2014). 
Among several other evidences, healthy pigs treated with proteasome 
inhibitor showed hypertrophy and reduced heart function (Herrmann et al. 
2013). In contrast, inhibiting proteolysis by PS-519 suppressed leukocyte 
infiltration, which diminished fibrotic deposition after myocardial infarction 
(Stansfield et al. 2007). Proteolysis blockage was reported to enhance 
cMyBP-C expression in hypertrophic cardiomyopathy (Carrier et al. 2009; 
Powell et al. 2012). Some components were connected with heart disease 
progression as in the case of the E3 ligase FBXO32, a homozygous 
mutation of this factor was associated with familial dilated cardiomyopathy 
(Al-Yacoub et al. 2016). Other E3 ligases, such as Atrogin-1, were 
presented to react with calcineurin and promote its degradation. Together, 
these evidence indicate that a proper balance of ubiquitination is crucial for 
heart function. Despite the controversial data about the actual roles, many 
studies indicate the dysfunction of ubiquitination in human cardiomyopathy, 
and its impairment in animal models supports this observation (Kumarapeli 
et al. 2005; Pagan et al. 2013; Spänig et al. 2019). 

As discussed above, the ubiquitination machinery can be explored for 
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therapeutic approaches in cardiac diseases. For example, the MuRF family 
plays crucial roles in heart function, by which the deficiency of MuRF1 and 
MuRF3 protein in double mutant mice led to hypertrophic cardiomyopathy 
(Fielitz et al. 2007). The E3 complex Fbox32-MAFbx-Atrogin-1 mediates the 
susceptibility of cardiomyocytes in response to cardiac injuries through its 
impacts on apoptosis (Xie et al. 2009). Among the ubiquitination factors 
functioning negatively to the heart, cylindromatosis (CYLD) is one of the 
most characterised DUBs. It was reported to induce transdifferentiation of 
adventitial fibroblasts associated with vascular remodelling (Yu et al. 2017). 
In addition, CYLD deficient mice exhibited improved survival with less 
cardiac fibrosis and apoptosis in pressure overload condition (Wang et al. 
2015a). 

In conclusion, these information are concordant in indicating that 
targeting ubiquitination in the heart can possibly lead to the development of 




2. AIM OF THESIS 
The works described in this thesis is aimed at identifying the 
ubiquitination factors regulating cardiomyocyte proliferation. Using an 
unbiased High Throughput Screening approach, we performed a large 
scale of siRNA-based screening targeting the ubiquitination-proteasome 
pathway in neonatal mouse cardiomyocytes, followed by the analysis of 
cardiomyocyte proliferation using siRNAs against the identified top hits. 

The screening led to the discovery of eleven top factors essential for 
cardiomyocyte replication. After that, we validated these factors and tested 
their capacity to enhance cardiomyocyte proliferation using an Adeno-
Associated Virus (AAV) vector to overexpress these candidates in neonatal 
cardiomyocytes. These results led to the identification of an E2 conjugating 
enzyme named UBE2G1 induced significantly cardiomyocyte replication 
and thus was selected for further investigation. 

We deepened our study by silencing this factor and evaluated its crucial 
role in cardiomyocyte replication in normal conditions and upon the 
stimulation of proliferation using a series of miRNAs that the laboratory had 
previously identified. We expanded our investigation on UBE2G1 by 
assessing whether this factor works through the ubiquitination cascade. To 
better understand the impact of UBE2G1 on cell replication, we examined 
the expression of cell cycle regulators and the activation of several signal 
transduction pathways.     

Next, we validated the effects of UBE2G1 overexpression in enhancing 
cell replication in a neonatal mouse model. We also assessed its potential 
in protecting the heart after myocardial infarction in an adult mouse model.  

Our findings provide new insights into UBE2G1 function on the 
proliferation of cardiomyocytes while proposing a further direction to 
investigate the UBE2G1 molecular mechanism in the heart.      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3. MATERIALS AND METHODS

3.1 Cell culture methods 
3.1.1. Human embryonic kidney 293T line (HEK293T) 
HEK293T cells were purchased from ATCC and cultured in DMEM 1g/L 
glucose (Life Technologies), 10% foetal bovine serum (FBS) (Gibco) and 
100 U/ml penicillin and 100 mg/ml streptomycin (Sigma). 

3.1.2. Primary neonatal mouse ventricular cardiomyocytes 
The hearts, harvested from 1-2 days old newborn mice, were transferred 
in ice-cold CBFHH buffer (calcium and bicarbonate-free Hanks with 
HEPES). Ventricles were separated from atria, and the tissue was minced 
into small pieces down to a diameter of 2-3 mm, digested with 0.5% 
Trypsin-EDTA solution (Life Technologies) at the final concentration 0.1 mL 
per mg of tissue in 4 minutes incubation at 37°C. The supernatant was 
collected in ice-cold FBS after each incubation. The digestion was 
repeated for 6-8 times. Cell suspension was filtered through a 40 µm 
strainer (BD Falcon) and centrifuged for 10 minutes at 1,500 rpm. The cells 
were resuspended in DMEM 4.5 g/L glucose, 10% FBS and pre-plated for 
2 hours on 100 mm dishes to allow the fibroblast attachment. The 
supernatant containing mainly cardiomyocytes was then collected and 
plated on primary culture plates with DMEM 4.5 g/L glucose, 5% FBS, 20 
mg/ml vitamin B12 (Sigma), 100 U/ml penicillin and 100 mg/ml 
streptomycin (Sigma).

3.1.3. Primary neonatal rat ventricular cardiomyocytes 
After sacrificing neonatal Wistar rats (1-2 days old), the hearts were 
harvested and transferred in CBFHH buffer. The ventricles were separated 
from atria and the tissue was minced into small pieces down to a diameter 
of 2-3 mm and dissociated in CBFHH buffer containing 2 mg/ml of Trypsin, 
20mg/ml of DNAse II and 80 ug/ml of Gentamicin. The digestion was 
performed in a fresh buffer for approximately 10 rounds of 10 minutes each 
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round with slow stirring at 37°C, followed by pipetting up and down. After 
each digestion, the supernatant was collected in warm FBS. At the end of 
digestion, cell suspension was filtered through a 40 µm strainer (BD Falcon) 
and centrifuged for 10 minutes at 1,500 rpm. The cells were resuspended in 
DMEM 4.5 g/L glucose, 10% FBS and pre-plated for 2 hours on 100 mm 
dishes to allow the fibroblast attachment. The cardiomyocytes, after this 
passage, were mainly present in the supernatant and easily collected for 
plating at the desired density in primary culture plates with DMEM 4.5 g/L 
glucose, 5% FBS, 20 mg/ml vitamin B12 (Sigma), 100 U/ml penicillin and 
100mg/ml streptomycin (Sigma). 
3.1.4. Plasmid cloning and AAV vector production  
For AAV vector production, I had amplified the cDNAs of the selected 
factors PCR, then purified and cloned them into a plasmid backbone 
containing Flag-tag under the CMV promoter. Three-hundred µg of plasmid 
was used for AAV preparation. Vectors were generated by the AAV Vector 
Unit (AVU) at ICGEB Trieste (http://www.icgeb.org/avu-core-facility.html) as 
described previously with a few modifications (Arsic et al. 2004). Briefly, the 
infectious recombinant AAV vector particles were generated in HEK293T 
cells cultured in roller bottles by a cross-packaging approach whereby the 
vector genome was packaged into AAV capsid serotype 9 or AAV capsid 6. 
Viral stocks were obtained by PEG precipitation and CsCl2 gradient 
centrifugation. The titer of recombinant AAVs was calculated by quantifying 
vector genomes (vg) packaged into viral particles, by using a real-time PCR 
calculated a standard curve of a plasmid containing the vector genome; the 
titer was in the range of 1x1012 to 1x1013 (vg/ml). 

3.1.5 Primary neonatal cardiomyocytes transduction 
After 24 hours of isolation, primary neonatal cardiomyocytes were 
incubated with AAV6 vectors at a multiplicity of infection (MOI) ranging from 




3.1.6 siRNA/miRNA transfection on neonatal cardiomyocytes  
The siRNA or miRNA mimics were transfected into a neonatal rat or 
neonatal mouse cardiomyocytes using either an optimised reverse or 
forward transfection protocols. The following procedures and volumes refer 
to a well of 96 multi-well plate. For each reaction, 0.2 µl of Lipofectamine 
RNAiMAX (ThermoFisher) were diluted in 25 µl of Opti-MEM Reduced 
Serum Medium (ThermoFisher) and incubated for 5 minutes before adding 
to 7.5 μl of siRNA or miRNA mimic (500 nM stock concentration, 25 nM 
final concentration). The transfection mixture was incubated for 30 minutes 
at room temperature and then transferred into the 96 multi-well plate. The 
medium was changed after 24 to 48 hours of transfection. 

3.1.7 Cell cycle analysis 
For flow-cytometric analysis of DNA content, the cardiomyocytes were 
harvested after 48 hours of transfection. The cells were fixed in 4% PFA for 
15 minutes, permeabilized in 1% Triton X-100 in PBS for 20 minutes, 
blocked in 2% BSA (Roche) in PBS for 30 minutes, then stained with an 
antibody against sarcomeric α-actinin (ab90776, Abcam) in the blocking 
solution for 10 minutes and subsequently incubated with Hoechst 33342 
(Life Technologies) for 10 minutes. After that, the cells were washed with 
PBS to remove the staining solution, centrifuged and resuspended in PBS. 
Cell suspensions were analyzed at the FACS Celesta Cytometer (BD). 
Analysis of the data was performed on FlowJo X software. 

For the work described in this section, I would like to acknowledge the 
contribution of Ilaria Secco, PhD.   

3.1.8 Immunofluorescence on primary cell cultures 
To study cell cycle status of in vitro treated cardiomyocytes, we used the 
Click-IT technology to visualize the incorporation of the thymidine analogue 
EdU, added to the cell culture medium at 20 hours before the fixation. The 
cardiomyocytes were separated from the containing non-myocyte cells by 
a specific staining with cardiac sarcomeric α-actinin. Briefly, primary 
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cardiomyocytes were fixed with 4% PFA for 10 minutes, permeabilized with 
0.5% Triton X-100 in PBS for 10 minutes, followed by 30 minutes blocking 
in 1% BSA in PBS. The cells were stained overnight with an antibody 
against sarcomeric α-actinin diluted in blocking solution at 4°C. After that, 
the cells were washed with 0.2% Tween-20 in PBS and incubated for 2 
hours with relevant secondary antibodies conjugated to Alexa Fluor Dyes 
(LifeTechnologies). Eventually, the cells were stained by the Click-IT EdU 
594 Imaging kit (Life Technologies) to detect EdU incorporation, according 
to the manufacturer’s instructions, followed by the final staining with 
Hoechst 33342. 

3.2 High Throughput Screening 
The work described in this section was performed with the technical 
assistance of Luca Braga, PhD and the supervision of Hashim Ali, PhD. 
A murine library of more than 600 siRNAs of known ubiquitination factors 
(Dharmacon) was used to transfect in neonatal mouse cardiomyocytes. 
Using a liquid handler (Hamilton) to dilute siRNAs from the library, 5 µl of 
siRNA (500nM stock concentration) was pipetted into each well of a 384-
wells plate (Perkin Elmer), leaving space for controls on either side. A pre-
incubated mixture of RNAiMAX and Opti-MEM was added to each well 
using a multi-well dispenser and incubated for 30 minutes. The suspension 
containing isolated cardiomyocytes was added to each well in DMEM 4.5 
g/L glucose, 5% FBS, 20 mg/ml vitamin B12 without antibiotics. After 72 
hours transfection, EdU was added in the culture medium, and the cells 
were fixed after 20 hours of incubation. Immunofluorescence was 
performed as previously described to exclude the contribution of 
contaminating fibroblast from the quantification.

High content fluorescent images were acquired using the ImageXpress 
micro microscope (Molecular Devices) and analysed using MetaXpress. A 
total of 12 images were acquired per well for each wavelength. 
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Cardiomyocytes were detected in the primary cultures by their positivity for 
sarcomeric α-actinin.

3.3 Molecular biology methods  
3.3.1 Generation of the plasmid collection  
The coding sequence of selective gene was amplified through PCR from 
extraction samples of the mouse heart. Gel extraction and PCR clean up 
were performed using Wizard SV Gel and PCR Clean-Up System (Promega) 
following the manufacturer’s instructions. After that, the amplicon was 
cloned directly into pAAV-CMV plasmid available in the AAV Unit. The 
plasmid was transformed into XL10-Gold ultracompetent cells (Stratagene) 
and prepared using NucleoBond Xtra Midi or Maxi EF kit (Macherey-Nagel) 
following the manufacturer’s instruction. Plasmid sequencing was done by 
GATC Services (Eurofins Genomics). For evaluating of protein expression, 
cloned plasmid was transfected in HEK293T and examined with western 
blotting. These plasmids were used for AAV vector preparations. 

Primers for cloning (5’-3’): 















































3.3.2 RNA isolation and quantitative real-time PCR 
Total RNA was extracted by using QIAzol (QIAGEN) following the 
manufacturer’s instruction. RNA quantification was carried out by using 
Qubit 2.0 Fluorometer (Invitrogen). An amount of 0.5-1 µg of the total RNA 
was reverse transcribed using Random primers (Invitrogen) and M-MLV 
reverse transcriptase (Invitrogen). All the quantitative real-time PCR were 
performed on a BioRad CFX96 using TaqMan probes (Applied Biosystem) 
or SYBR (Promega). A dissociation curve was used to confirm primer 




- Gapdh 	 Mm99999915_g1

- Hprt  	 Mm01545399_m1

- Ube2g1 	 Mm00482548_m1

- Notch1 	 Mm00627185_m1

- Hey1 	 Mm00468865_m1

- Hes1 	 Mm01342805_m1

- CyR61  	 Mm00487499_m1

- Ctgf  	 Mm01192933_g1

Primers for quantitative real-time PCR with SYBR:



















- Cyclin D1  	 Fwd: AGAAGTGCGAAGAGGAGGTC   

	 Rev: CTTAGAGGCCACGAACATGC 

















3.3.3 Western blotting 
To assess the protein levels of several proteins, samples were lysed in 
RIPA buffer (50 mM Tris‐HCl, pH 7.2; 150 mM NaCl; 1% Triton X‐100) 
complemented with Protease Inhibitor Cocktail (Roche) for 30 minutes at 
4°C. Protein quantification was done by Bradford assay (BioRad). The 
samples were resuspended with Laemmli sample buffer (0.19 M Tris-HCl, 
pH 6.8; 0.015% bromophenol blue; 30% glycerol; 3% SDS; 3% 2-
mercaptoethanol) and denatured by boiling for 5 minutes at 90°C. Then, 
they were resolved by SDS-PAGE of the relevant percentage according to 
the protein of interest. Total proteins were transferred at 350 mA for 90 
minutes at room temperature onto nitrocellulose membrane (GE Healthcare) 
and then blocked in 5% milk TBST for 1 hour at room temperature. The 
membrane was incubated overnight with primary antibody at 4°C. After 
that, the membrane was washed with TBST for 3 times and incubated with 
secondary antibody conjugated with horseradish peroxidase for 1 hour at 
room temperature. Following the membrane development, the band 




The following antibodies were used in this study:

- Flag M2-HRP	 A8592, Sigma-Aldrich

- β-Actin-HRP 	 A3854, Sigma-Aldrich

- UBE2G1 	 PA5-30201, Thermo Fisher	 

- CDT1	 sc-365305, Santa Cruz

- pERK1/2	 9106, Cell Signaling

- Cleaved Notch1 (Val1744) 	 BK2421L, Cell Signaling 

- YAP	 4912S, Cell Signaling

- pYAP (S127)	 4911S, Cell Signaling

- Tubulin	 T5168, Sigma-Aldrich

3.3.4 Immunoprecipitation 
HEK293T cells were transfected with the plasmids using FuGENE HD 
transfection reagent (Promega). After 48 to 72 hours of transfection, cells 
were washed with cold PBS and lysed with RIPA buffer for 30 minutes at 
4°C. Samples were then sonicated and quantified with Bradford assay 
(BioRad). For one round of IP, approximately 0.5-1 mg total protein was 
incubated with pre-equilibrated anti-Flag M2 magnetic beads or dynabeads 
pre-conjugated with target antibodies on a rotating wheel at 4°C for 2 
hours. Then, the beads were washed 5 times with cold lysis buffer, resolved 
in Laemmli sample buffer and examined by western blotting with specific 
antibodies.  

3.3.5 Silver staining 
After resolving samples by SDS-PAGE, the gels were placed in fixative 
solution (40% ethanol, 10% acetic acid) for 20 minutes and subsequently 
stained with SilverQuest™ Silver Staining Kit (Life Technologies) following 
manufacturer’s instruction. 

3.3.6 Proteome Profiler Array 
After 48 hours of transfection or transduction, cardiomyocytes were 
treated with 10 µM of proteasome inhibitor MG132 (Calbiochem) for 2 
hours. Then, the samples were washed with cold PBS and lysed with lysis 
buffer (supplied by the kit and complemented with 10 μg/mL Aprotinin, 10 
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μg/mL Leupeptin and 10 μg/mL Pepstatin) for 30 minutes at 4°C. The 
lysates were centrifuged at 14,000g for 5 minutes and transferred into a 
clean tube. After the quantification, around 250 µg of total protein lysates 
were used for the next step following the manufacturer’s instruction. In 
brief, the cell lysates were incubated at 4°C overnight with the membranes 
(supplied by the kit) on a shaker. Then, the membranes were washed for 3 
times with the washing buffer (supplied by the kit), and incubated with the 
detection antibody cocktail (supplied by the kit) at room temperature for 2 
hours. After the incubation, the membranes were washed for 3 times with 
the washing buffer and subsequently incubated for 30 minutes with the 
Streptavidin-HRP (supplied by the kit). The membranes were eventually 
washed and developed with Chemi Reagent Mix (supplied by the kit).  

3.3.7 Nuclear-cytoplasmic fractionation 
After 72 hours of transfection or transduction, cardiomyocytes were 
washed with cold PBS and harvested in 100 μl of hypotonic buffer (50 mM 
Tris pH7.5, 10 mM NaCl, 3 mM MgCl2, 10% glycerol) supplemented with 
protease inhibitors (Roche) and phosphatase inhibitors (cocktail 3 Sigma, 
2mM orthovanadate, 1 mM NaF). After 1 minute incubation, the cells were 
collected and NP40 was added to 0.1% final concentration. After 5 minutes 
on ice, the cells were centrifuged at 4,000 rpm for 5 minutes at 4°C; the 
supernatant and cytosolic fractions were then recovered. The pellets were 
resuspended in 150 μl IPLS buffer (50 mM Tris pH 7.5, 120 mM NaCl, 1 mM 
EDTA, 0.5% NP40, supplemented with the same inhibitors as above) and 
sonicated. Nuclear lysates were centrifuged at 16,000rpm for 20 minutes at 
4°C and the supernatant was recovered as the nuclear fraction. Protein 
concentration of cytoplasmic and nuclear lysates was measured using the 
Bradford assay (BioRad). A total of 25 μg protein lysates were used for 




3.4 Animal experimentations 
Animal care and treatment were conducted in conformity with 
institutional guidelines in compliance with national and international laws 
and policies (European and Economic Council Directive 86/609, OJL 358, 
December 12, 1987), upon approval by the ICGEB Institutional Animal 
Welfare Board and by the Italian Ministry of Health.

Among the procedures described in this section, echocardiography, 
intracardiac injection and myocardial infarction were performed by Simone 
Vodret, PhD. 

3.4.1 Intraperitoneal injection in neonatal mice 
Postnatal CD1 mice (P0-P1) received roughly 30 µl of injection solution 
intraperitoneal by Microfine Plus 0.3 ml Insulin Syringe 8 mm/30 gauge 
(BD). Every mouse received approximately 3x1011 AAV9 vectors. Following 
day, EdU was injected in the mice with dosage adjusted by animal body 
weight at 30 g/kg final concentration. Edu injection was repeated every 
other day for 7 days. 

3.4.2 Intracardiac injection in adult mice 
Adult CD1 female mice were anesthetized by intraperitoneal injection of 
ketamine (40 µg/g, Imalgene 1000) and xylazine (100 µg/g, Sigma), at a 
dosage of 1.2 to 1.3 μl/g and intubated. Thorax was incised, the fifth 
intercostal space was cut and enlarged to expose heart anterior wall. 
Maximum 30 µl of AAV9 suspension (ranging from 6x1010 to 3x1011) was 
injected into the left ventricle. After injection, the thorax was sutured and 
mice were extubated to re-establish normal breathing.

3.4.3 Myocardial infarction 
Myocardial infarction was introduced in adult CD1 mice (8 to 12 weeks 
old) by permanent left anterior descending (LAD) coronary artery ligation. 
The mice were anaesthetised on a warming pad (37°C) and endotracheally 
intubated on a rodent ventilator. Beating heart was accessed via a left 
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thoracotomy. After removing the pericardium, a descending branch of the 
LAD coronary artery was visualised with a stereomicroscope (Leica) and 
occluded with a nylon suture. Ligation was confirmed by the whitening 
partly of the left ventricle, immediately post-ligation. After that, the mice 
received an intracardiac injection of AAV9 vectors in the left anterior infarct 
border zone, as described above. The chest was then closed, and the mice 
were kept on the warm pad until they recovered spontaneous breathing.

3.4.4 Echocardiography 
Trans-thoracic two-dimensional echocardiography was performed at 15 
days, 30 days and 60 days after myocardial infarction. The mice were 
sedated with 5% isoflurane, using the Vevo 770 Ultrasound (VisualSonics), 
equipped with a 30-MHz linear array transducer. M-mode tracing was used 
to measure left ventricular anterior and posterior wall thickness, internal 
diameter at end-systole and end-diastole, fractional shortening and 
ejection fraction. 

3.4.5 Trichrome staining 
At the end of the studies, the heart was excised, briefly washed in PBS, 
and fixed in 10% formalin overnight at room temperature to proceed the 
embedded paraffin section and used for histology or immunofluorescence 
staining. Masson’s trichrome was used to stain the keratin and muscle 
fibers in red, collagen and bone in blue, cytoplasm in pink, and cell nuclei in 
dark brown to black. Tissue paraffin sections were deparaffinized (65°C for 
12 hours and xylene or bioclear for 2 hours at room temperature), 
rehydrated (5 minutes in 100% EtOH, 5 minutes in 95% EtOH, 5 minutes in 
75% EtOH, 5 minutes in 50% EtOH, and 5 minutes in water) and processed 
using a commercially available kit for Masson’s trichrome stain (BioOptica), 
according to the manufacturer’s instruction. Later, the slides were rapidly 




3.4.6 Immunofluorescence in paraffin-embedded tissue 
Four-μm thick tissue sections were de-waxed and rehydrated. Antigen 
retrieval was performed by boiling the sections in 10 mM sodium citrate 
buffer pH 6.0, 0.05% Tween-20 for 20 minutes and letting them cool down 
at room temperature for 2 hours. Sections were rinsed three times in water 
and permeabilised for 30 minutes in 0.5% Triton X-100 in PBS, then 
blocked for 1 hour in 2% BSA in PBS. Tissue sections were stained 
overnight at 4°C with an antibody against sarcomeric α-actinin. After that, 
the slides were washed in 0.05% Tween-20 in PBS, incubated for 2 hours 
with secondary antibody conjugated to Alexa Fluor Dyes (LifeTechnologies). 
Samples were further processed using the Click-IT EdU 594 Imaging kit 
and stained with Hoechst 33342. 

3.5 Statistical analysis 
Statistical analysis was performed by using a commercial software 
package (GraphPad Prism). Data are presented as mean ± standard error 
of the mean (s.e.m.). The comparison between two groups was performed 
by the Student’s t-test, that among different groups with one-way ANOVA 
or two-way ANOVA followed by post-hoc analysis using the Bonferroni’s 




4. RESULTS  
4.1 The identification of novel ubiquitination factors 
involved in cardiomyocyte proliferation    
Cardiomyocyte proliferation is essential for heart regeneration. So far, 
numerous studies reported attempts to reactivate the cardiac regenerative 
capacity. However, none of these studies tackled the role of ubiquitination 
in cardiomyocyte proliferation. Therefore, we decided to investigate the 
possible therapeutic role of ubiquitination in heart disease.

A high throughput screening (HTS) approach to identify cardiomyocyte 
regulators was performed successfully in the Molecular Medicine 
Laboratory (Eulalio et al. 2012). In this study, we exploited HTS to test a 
library of ubiquitination factors involved in cell replication. Our synthetic 
murine siRNA library includes more than 600 known members of 
ubiquitination (four different siRNAs for each gene). This library was used 
for reverse transfection in primary neonatal cardiomyocytes, and a 
proliferation assay based on 5-ethynyl-29-deoxyuridine (Edu) incorporation 
was implemented as a major readout after 72 hours (Figure 4.1A) (Edu is a 
modified thymidine analog that becomes incorporated in newly synthesized 
DNA). miR-199-3p and miR-590-3p were used as positive controls of 
proliferation. The screening was performed in duplicate, exhibiting good 
reproducibility between the two replicates (Pearson R=0.6104, p<0.0001). 
We assessed cell viability by counting the total cell number and evaluated 
the data distribution with the Shapiro-Wilk test. 

We observed that 592 siRNAs did not hamper cell viability, while the 
siRNAs exerting a toxic effect were excluded from further investigation. The 
results are shown in Figure 4.1B and are presented as log2 fold of 
cardiomyocyte proliferation of treated samples over controls. The silencing 
of several factors led to a significant decrease in cardiomyocyte 
proliferation, indicating an essential role of ubiquitination in this process 
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(Figure 4.1C). In parallel, knockdown of some factors resulted in an 
increase in cardiomyocyte proliferation. In this thesis, we focused mainly on 
the factors required for cell cycle progression.  

Figure 4.1: High throughput siRNA-based screening identifies ubiquitination 
factors involved in cardiomyocyte proliferation. A. Schematic of the screening and 
image reconstruction for quantification of proliferating cardiomyocytes. B. Screening 
results; the graph shows log2 fold of proliferative cardiomyocytes over control in two 
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replicate screenings (R1 and R2, Pearson R=0.6104, p<0.0001); the dotted lines 
indicate a 2-fold decrease of proliferation compared with control, selective factors are 
in red, miR-199-3p and miR-590-3p are in green. C. Cardiomyocyte proliferation of 
11 top factors and controls expressed as fold change over untreated 
cardiomyocytes, data are mean ± s.e.m (n = 3 independent experiments). D. 
Representative images of cardiomyocytes treated with siRNAs against selected 
factors and miRNA controls stained with Edu and ⍺-actinin. Scale bars 100 µm.

Eleven genes were selected for further analysis, including two E2 
conjugating enzymes (UBE2G1, UBE2E1), two deubiquitinating enzymes 
(OTUD7B, USP36), and seven E3 ligases (DCUN1D3, PHF5A, PRPF19, 
RBCK1, RNF181, RNF186, SOCS5) (Figure 4.1C). The selection of PHF5A 
was considered as a good indication of the efficacy of the screening since 
depletion of PHF5A was already reported to reduce the self-renewal 
potency of embryonic stem cells (Strikoudis et al. 2016). Maintenance of 
these genes appears to be essential for basal cell proliferation, thus we 
asked whether their overexpression might enhance cardiomyocyte 
replication. To answer this question, we generated the corresponding 
adeno-associated virus (AAV) to deliver them into primary cells.  

4.2 In vitro validation of the proliferative effect of the top 
factors  
To efficiently deliver the genes of interest in cardiomyocytes, we 
exploited the cardiac tropism and long-term expression of AAV6. We 
cloned the coding sequences of these genes into a plasmid AAV backbone 
including a Flag-tag and under the control of a CMV promoter. The cloning 
was assessed by sequencing and western blotting (Figure 4.2A). 

Next, we isolated neonatal cardiomyocytes and incubated them with 
AAV6 vectors expressing target proteins at the multiplicity of infection (MOI) 
of 5x104 (vg/cell) for 72 hours. This MOI was used as described in the 
previous works of our laboratory (Lovric et al. 2012; Ruozi et al. 2015). 
AAV6-Flag and miR-199 served as empty control and positive control of 
proliferation, respectively. The readout of this proliferation assay was Edu 
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incorporation into cardiomyocyte DNA (Figure 4.2B), and the experiment 
was performed in duplicate. 

 
Figure 4.2: In vitro evaluation of the proliferative effect of selective factors. A. 
Experimental workflow; the top hits were cloned into an AAV vector fused to a Flag-
tag; protein expression was checked by western blotting, individual AAV6 was 
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produced and used for proliferation assay. B. Representative images of 
cardiomyocytes stained with Edu and ⍺-actinin after AAV transduction (alpha-actinin, 
green, Edu, red). Scale bars 100 µm. C. Percentage of proliferating cardiomyocytes 
after AAV6 transduction, data are mean ± s.e.m (n = 3 independent experiments), 
*p<0.05, **p<0.01, one-way ANOVA.

We observed that the overexpression of a few genes was able to 
increase cardiomyocyte proliferation. In particular, the E2 conjugating 
enzyme UBE2G1 was the most significant factor in enhancing proliferation 
(Figure 4.2C). Therefore, we decided to further focus our attention on 
UBE2G1.

4.3 The depletion of UBE2G1 abolished the effect of pro-
proliferative miRNAs and induced hypertrophy 
After selecting UBE2G1, we investigated its role in cardiomyocyte 
function. Since the screening was performed using a pool of 4 siRNAs, we 
individually tested the four separate deconvoluted siRNAs. We found that 
siUBE2G1-3 was the most effective siRNA (Figure 4.3A) and used it in the 
following experiments. This experiment was performed only once due to 
the limited amounts of siRNAs cherrypicked from the screening library. 
After that, we validated the efficacy of silencing and overexpression of 
UBE2G1 at the mRNA and protein level. The results showed that siRNA 
treatment reduced the UBE2G1 mRNA level of 60%, while the AAV-
mediated overexpression strongly induced both mRNA and protein 
expression of UBE2G1 (Figure 4.3B and C).

Figure 4.3: Validation of silencing and overexpression of UBE2G1. A. 
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Cardiomyocyte proliferation after transfection with a single siRNA or a pool of four 
siRNAs against UBE2G1. B, C. UBE2G1 expression measured by qPCR and western 
blotting, data are mean ± s.e.m (n = 3 independent experiments), **p<0.01, one-way 
ANOVA. 

To confirm that UBE2G1 depletion blocked cardiomyocyte cell cycle 
progression, we also performed a Fluorescence Activated Cell Sorting 
(FACS) experiment. The data indicated that UBE2G1 silencing arrested 
cardiomyocytes significantly in the G1 phase compared with controls, 
subsequently reducing of 25% and 50% the cell numbers in S and G2/M 
phases, respectively (Figure 4.4A). 

Figure 4.4: The depletion of UBE2G1 abolished the pro-proliferative effect of 
miRNAs and induced hypertrophy. A. FACS analysis of cardiomyocyte cell cycle, 
data obtained from quantification of at least 1.5x104 cardiomyocytes for each 
condition, data are mean ± s.e.m (n = 3 independent experiments), *p<0.05, **p<0.01, 
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two-way ANOVA. B. Experimental flow chart of siUBE2G1 and miRNA co-
transfection. C. Representative images of cardiomyocytes stained with Edu and ⍺-
actinin after transfection. Scale bars 100 µm. D. Percentage of cardiomyocyte 
proliferation after siUBE2G1 and miRNA transfections (top panel), cardiomyocyte 
cross-sectional area after siUBE2G1 and miRNA transfections (bottom panel). Data 
are mean ± s.e.m (n = 3 independent experiments) *p<0.05, **p<0.01, t-test. 

Following this observation, we asked whether UBE2G1 was essential for 
the proliferation of cardiomyocytes after a strong stimulation to enter the 
cell cycle. Our laboratory had previously identified several miRNAs inducing 
cardiomyocyte proliferation, such as miR-199-3p and miR-590-3p, acting 
through different pathways (Eulalio et al. 2012; Torrini et al. 2019). 
Therefore, we decided to investigate the possible connection of UBE2G1 
and the pathways modulated by the pro-proliferative miRNAs. siRNA non-
targeting (siNT) and siUBE2G1 were co-transfected into neonatal 
cardiomyocytes with human miR-199a-3p, miR-590-3p, miR-302c, 
miR-373, and miR-1825 for 72 hours. C. elegans miR-67 served as a 
control in this experiment. Proliferation was assessed by EdU incorporation 
as previously described (Figure 4.4B). We observed that the depletion of 
UBE2G1 dramatically suppressed the pro-proliferative effects of all tested 
miRNAs (Figure 4.4C and 4.4D). Notably, we also observed that siUBE2G1 
impacted the cardiomyocyte phenotype (Figure 4.4C and 4.4D). Indeed, 
silencing UBE2G1 determined a significant increase in cardiomyocyte cell 
size and this hypertrophic response was also observed after treatment with 
all the tested miRNAs.

In summary, these results underlined the importance of UBE2G1 to 
cardiomyocyte cycling.

4.4 UBE2G1 acts through ubiquitination to modulate 
cardiomyocyte proliferation  
UBE2G1 is an E2 conjugating enzyme consisting of a putative E2 domain 
with one cysteine in the active site and it does not require an N-terminus 
nor a C-terminus domain for the catalysis (Polge et al. 2015). To better 
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understand if the effects of UBE2G1 on proliferation was mediated by the 
ubiquitination pathway, we generated a UBE2G1mutant by substituting the 
cysteine in the active site with alanine (Figure 4.5A). After that, we 
generated the corresponding AAV6 vector for the mutant protein (UBE2G1-
CA) and assessed its impact on proliferation. We found that AAV6-
UBE2G1-CA significantly reduced cardiomyocyte replication in a dose-
dependent manner (Figure 4.5B and C). Moreover, a slight, but  statistically 
significant, increase in cardiomyocyte cross-sectional area was also 
observed by this treatment, similarly to the siUBE2G1, suggesting a 





Figure 4.5: Mutation of the UBE2G1 catalytic site eliminates its proliferative 
effect. A. The scheme displays the UBE2G1 protein domains. The mutation of the 
catalytic site (Cysteine replaced by alanine, C>A) was introduced at the position in 
red. B. Representative images of proliferative cardiomyocytes after transduction with 
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increasingly higher MOIs of AAV6-UBE2G1, AAV6-UBE2G1-CA and AAV6-MCS, 
which was used as a control. Scale bar 100 µm. C. Percentage of cardiomyocyte 
proliferation after transduction (top panel), cardiomyocyte cross-sectional area after 
transduction (bottom panel); data are mean ± s.e.m (n = 3 independent experiments); 
*p<0.05, **p<0.01, two-way ANOVA. 

Altogether, these data demonstrate that UBE2G1 triggers proliferation through 
ubiquitination and that a mutation in the active site abrogates this effect.

4.5 Identification of UBE2G1 partners  
Since we observed that UBE2G1 acts through ubiquitination, we wanted 
to define its targets. UBE2G1 was previously associated with the E3 
complex CRL1Skp1 for the regulation of CDT1 stability in human colon 
cancer cells. CDT1 is a well-known factor modulating DNA replication 
(Shibata et al. 2011; Pozo and Cook 2016). Thus, we wanted to evaluate 
whether UBE2G1 might function through CDT1 in the cardiac context 
(Figure 4.6A).  
Figure 4.6: Investigation of possible interaction between UBE2G1 and E3 
ligases. A. Scheme displays the possible connection of UBE2G1 and CRL1Skp1 
complex to regulate CDT1 stability. B. Western blot results after immunoprecipitation 
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to detect the interaction of UBE2G1 and CDT1. C. Western blot results followed 
immunoprecipitation to detect the interaction of UBE2G1 with different E3 ligases. 
Immunoprecipitation was applied to pulldown CDT1 and its interacting 
partners. As mentioned in the literature, we were able to detect an 
interaction between CDT1 and CUL1, but could not observe any binding 
between UBE2G1 and CDT1 in this setting (Figure 4.6B).

We decided to examine further a possible connection between UBE2G1 
and the ligases discovered in the screening as potential modulators of cell 
cycle progression. We co-transfected the UBE2G1 plasmid with the 
indicated ligase into HEK-293 cells and then immunoprecipitated them 
using Flag beads. Unfortunately, we could not detect any interaction 
(Figure 4.6C).

4.6 The interplay of UBE2G1 with various modulators to 
regulate proliferation 
As previously shown, the silencing of UBE2G1 blocks proliferation. 
Therefore, we wanted to investigate which cell cycle regulators were 
affected by UBE2G1 silencing. To answer this question, we examined the 
mRNA and protein levels of several cell cycle regulators.

Upon treatment with siUBE2G1, we found that p27 expression was 
significantly induced, looking at both mRNA and protein levels (Figure 
4.7A). In parallel, the reduction of Cyclin D1, Cyclin E, and p15 expression 
was confirmed by quantitative PCR (Figure 4.7A). We could not detect 
Cyclin D and p15 proteins with our antibodies. 

To better investigate additional pathways involved in UBE2G1 action, we 
analysed a commercial phosphorylation profile of cardiomyocytes upon 
overexpression and silencing of UBE2G1. Forty-three common kinases 
were tested. We found that the phosphorylation of GSK-3β, ERK1/2, and 
STAT3 proteins was significantly altered following our treatments (Figure 
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4.7B and C), suggesting a possible interaction of UBE2G1 with these 
pathways to allow cell cycle progression. 
Figure 4.7: UBE2G1 affected cell cycle regulators and different kinases. A. 
Depletion of UBE2G1 affects the transcriptional levels of p15, p27, Cyclin D1, cyclin 
E and the protein levels of p27 and Cyclin E. B. Representative blots after the 
development of proteome profiler phospho-kinase array, reference spots are in black; 
C. Quantification of samples treated with siUBE2G1 or AAV6-UBE2G1 normalized by 
untreated sample, obtained as in (B). Data are mean ± s.e.m (n = 3 independent 
experiments), *p<0.05, **p<0.01, two-way ANOVA. 

A few essential signalling pathways known to regulate cardiomyocyte 
proliferation were not included in the previous commercial panel. In 
particular, we wondered whether the master regulators of cardiomyocyte 
proliferation Notch and Hippo pathways were connected with the UBE2G1 
mechanism of action. To clarify this question, we performed a nuclear and 
cytoplasmic fractionation experiment to assess the protein levels of the 
Notch1 intracellular domain (NICD), phosphorylated YAP (Serine 127), and 
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total YAP. The p84 protein and Tubulin levels were used as controls of the 
fractionation procedure. We observed a reduction of the NICD protein level 
in the nucleus upon UBE2G1 silencing, and the opposite effect after its 
overexpression (Figure 4.8A). These observations are consistent with the 
known role of NICD in regulating neonatal cardiomyocyte proliferation, not 
necessarily implying a direct function of UBE2G1 in the Notch1 pathway. 
On the YAP side, upon UBE2G1 overexpression, we observed a reduction 
of YAP phosphorylation at Serine 127, which promoted YAP degradation 




Figure 4.8: The interaction of UBE2G1 with Notch1 and Hippo pathways. A. 
Representative blots showing the protein levels of nuclear and cytoplasmic NICD, 
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phosphorylated YAP (Serine 127), and total YAP of treated samples. p84 and Tubulin 
served as controls of cellular fractionation. The numbers show blot quantification of 
siUBE2G1 normalized by siNT, and AAV6-UBE2G1 normalized by AAV6-MCS. B. 
Relative expression of Notch1, Hey1, and Hes1 of indicated samples. Data are 
mean+s.e.m. C. Relative expression of Ctgf, CyR61, and Anf of indicated samples. 
Data are mean ± s.e.m (n = 3 independent experiments), *p<0.05, one-way ANOVA. 

We further investigated these pathways by quantifying the expression of 
Notch1 and its downstream genes (Hey1 and Hes1) at the mRNA levels, 
and the same applied for YAP-responsive genes such as Ctgf, CyR61, and 
Anf. Consistent with the previous results, our data showed the reductions 
of Notch1 and Hey1 expression upon treatment with siUBE2G1 while the 
overexpression of UBE2G1 induced the mRNA expression of Notch1, Hey1 
and Hes1 (Figure 4.8B). Intriguingly, we observed that siUBE2G1 treatment 
exerted a significant induction of Anf expression, a known hypertrophic 
marker (Figure 4.8C). This result was relevant to the previous data shown 
in panel 4.3. No significant change was observed for Ctgf and CyR61, 
connected with Yap induced proliferation (Figure 4.8C).

In conclusion, our data show that UBE2G1 acts through numerous 
mechanisms and signalling pathways to mediate cardiomyocyte replication. 
However, the direct target(s) remains still unknown.

4.7 UBE2G1 overexpression increases cardiomyocyte 
replication in vivo and preserves cardiac function at an 
early time point after myocardial infarction        
Our data showed that the upregulation of UBE2G1 increases proliferation 
in vitro. Hence, we asked whether AAV-UBE2G1 was able to enhance 
proliferation in vivo. To answer this question, we injected AAV9-UBE2G1 in 
neonatal mice and looked at myocyte proliferation after 7 days.  AAV9-MCS 
and AAV9-miR-199 were used as empty control and positive control of 
proliferation, respectively. The AAVs were injected intraperitoneally in 
neonatal mice (postnatal day 0) at a MOI of 3x1011 (vg per animal). EdU 
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was injected at a dose of 30 mg/kg, every other day until sacrifice (Figure 
4.9A). Frozen tissue was used to evaluate transgene overexpression, while 
paraffin-embedded tissue was used to assess cell proliferation.

Figure 4.9: UBE2G1 overexpression increases cardiomyocyte replication in vivo. 
A. Experimental flowchart; each mouse was injected with 3x1011 viral particles and 
received EdU every other day before heart collection. B. Representative images of 
EdU-positive cardiomyocytes from the heart sections with the indicated treatments. 
Scale bar 50 µm. C. Percentage of cardiomyocyte proliferation at 7 days after 
injection. Data are from the quantification of over 2000 cardiomyocytes in each 
animal. Data are mean ± s.e.m (n ≥ 5 animals per condition), *p<0.05, t-test. D. 
UBE2G1 relative expression from the heart of treated mice; data are mean ± s.e.m (n 
= 3 independent experiments), *p<0.05, **p<0.01, t-test.

We observed a significant increase of EdU positive cardiomyocytes in 
the AAV9-UBE2G1 treated group compared with the control group (Figure 
4.9B and C; the data show the counts of at least 2000 alpha-actinin 
positive cardiomyocytes per animal, from two independent experiments. 




Then, we moved to adult mice to test the ability of UBE2G1 in preserving 
heart function after myocardial infarction (MI). Adult mice underwent 
permanent ligation of the left anterior descending coronary artery and were 
immediately injected with 3x1011 viral particles of AAV9-UBE2G1 or AAV9-
MCS. Animals were monitored by echocardiography for two months. We 
measured the left ventricle ejection fraction (EF) and left ventricular anterior 
wall thickness (LVAWd) at 15, 30, and 60 days after MI (Figure 4.10A). 

Figure 4.10: UBE2G1 overexpression preserves heart function at early time 
points after myocardial infarction. A. Experimental flowchart (Echo: 
echocardiography). B. Heart function at indicated time points (EF, Ejection Fraction; 
LVAWd, Left Ventricular Anterior Wall thickness). Data are mean ± s.e.m (n ≥ 10 
animals per condition), *p<0.05, t-test; C. Representative images of the heart 
sections after Masson trichrome staining at 60 days after MI, fibrotic areas are 
stained in blue. D. Quantification of infarct size expressed as the percentage of left 
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ventricular volume. E. UBE2G1 relative expression from the heart of treated mice at 
60 days after MI. F. Representative images of proliferating cardiomyocytes from the 
heart sections of treated mice. Scale bar 20 µm. G. UBE2G1 relative expression from 
the heart of treated mice normalized by control mice at 7, 15, and 30 days after 
injection.

The results showed significant preservation of LVAWd and EF in the 
treated group compared to control at 15 and 30 days after MI. However, we 
could not see a relevant difference between the two groups at 60 days 
(Figure 4.10B). After sacrifice, paraffin-embedded tissues were used to 
monitor tissue fibrosis by trichrome staining. We did not observe any 
difference in the infarct size between the two groups (Figure 4.10C and D). 
To better understand this unexpected result, we quantified the transgene 
overexpression at two months after injection. UBE2G1 expression was 
barely detected (Figure 4.10E). In parallel, EdU positive cardiomyocytes 
were almost undetectable at this late time point (Figure 4.10F).

Observing the low expression of UBE2G1, we wondered whether this 
was a possible explanation for the low preservation of cardiac muscle (no 
difference in infarct size). To answer this question, we performed a time-
dose-dependent experiment in adult mice. CD1 animals received 
intracardiac injection with the MOI 3x1011, or 6x1010 of AAV9-UBE2G1 and 
were sacrificed at 7, 15, and 30 days after injection to quantify UBE2G1 
expression. On day 7, we observed a 40-fold increase in the UBE2G1 
mRNA in mice injected with a higher dose of AAV9-UBE2G1 compared with 
control mice. Only 5-fold enrichment was detected in the mice injected with 
a lower dose of AAV9-UBE2G1 (Figure 4.10G). However, UBE2G1 
expression started to decline dramatically in both groups at 15 days after 
injection (Figure 4.10G). Thus, this loss of UBE2G1 expression over time, 
possibly due to a toxic effect on the expressing cells, might partially explain 






In this work, we report the results of a high throughput screening, 
fluorescence microscopy-based, in neonatal mouse cardiomyocytes using 
a library of siRNAs against more than 600 target mRNAs coding for proteins 
in the ubiquitination to search for the factors involved in cardiomyocyte 
proliferation. 

Ubiquitination plays a crucial role in proteostasis to ensure a continuous 
turnover of proteins, remove misfolded molecules, and recycle those no 
longer needed by the cells (Pagan et al. 2013). Loss of cellular protein 
homeostasis results typically in proteotoxic stress and accumulation of 
reactive oxygen species (ROS) (Dunlop et al. 2009). This condition is 
commonly associated with the pathogenesis of aging-related diseases 
such as neurodegenerative and cardiovascular disorders. In particular, 
cardiomyocytes have minimal regenerative capacity that lessens 
proteotoxic removal happening through cell division, and their high 
metabolic demand favours reactive oxygen species (ROS) accumulation 
(Hofmann et al. 2019). Targeting ubiquitination represents an unexploited 
therapeutic approach in heart diseases (Henning and Brundel 2017) and 
several studies have already supported this concept. For example, 
treatment with lactacystin (a proteasome inhibitor) prolonged the half-life of 
myosin heavy chain (Eble et al. 1999), or dysfunction of ubiquitination 
promoted cardiac hypertrophy and heart failure (Chen et al. 2005). 

In this context, my research project was specifically aimed at identifying 
the factors in the ubiquitination system that function as positive regulators 
of cardiomyocyte proliferation. On the one hand, this can provide new 
insights into the mechanisms regulating the cardiomyocyte cell cycle while, 
on the other, it can lead to the identification of new possible targets for the 
development of regenerate therapies in the heart.

Some ubiquitination factors essential for cardiomyocyte proliferation 
were identified from our large scale screening, including E2 conjugating 
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enzymes, E3 ligases, and deubiquitinases. Among the top eleven hits of 
factors I found to act as crucial regulators of cardiomyocyte replication, we 
found the E3 ligase PHF5A. This identification was considered as a good 
marker of the screening efficacy since PHF5A depletion was already 
reported to reduce the self-renewal potency of embryonic stem cells 
(Strikoudis et al. 2016). Interestingly, most of the identified genes have not 
been associated with cardiomyocyte replication so far, strengthening the 
novelty of our study. 

Since the knock-down of these genes hampered cell proliferation, we 
asked whether their overexpression, on the contrary, might enhance 
cardiac myocyte replication. To efficiently deliver the genes of interest into 
cardiomyocytes, we exploited the cardiac tropism and long-term 
expression of Adeno-Associated Viral (AAV) vectors, largely used for both in 
vitro and in vivo gene delivery in our laboratory (Lovric et al. 2012; Ruozi et 
al. 2015; Gabisonia et al. 2019). We observed that the overexpression of a 
few of the selected genes including DCUN1D3, SOCS5 and UBE2G1 could 
induce cardiomyocyte proliferation in vitro. Some E3 ligases, such as 
MuRF1, FBXO32, or MDM2, were reported to protect the heart against 
either oxidative stress or ischaemia-reperfusion injury (Brown et al. 2017b; 
Dadson et al. 2017). Our results added DCUN1D3 and SOCS5 to the group 
of E3 ligases potentially interesting to provide a beneficial effect to the 
heart. The most interesting factor from this validation assay was the E2 
conjugating enzyme UBE2G1, which exhibited the strongest pro-
proliferative effect and thus was selected for further investigation. Much of 
E2 functions remain to be discovered in the heart, UBC9 is a rare E2 
enzyme that was identified to regulate proteostasis in cardiomyocytes 
(Gupta et al. 2014), while the factor that associate to myocyte replication 
mostly remain still elusive.   

The human UBE2G1 gene is located on chromosome 17p13.3 and 
encodes a highly conserved, but poorly characterised, E2 conjugating 
enzyme, which was initially described in a medulloblastoma study (Cvekl Jr 
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et al. 2004). This enzyme is known to synthesise K-48 polyubiquitin without 
E3 ligase through a still poorly understood mechanism, and its acidic loop 
plays an essential role in this process (Choi et al. 2015). The UBE2G1 
protein possesses a single catalytic domain with a crucial cysteine residue 
in the active site. The binding of modified ubiquitin to the backside of 
UBE2G1 was reported to interfere with the formation of thioester-linked of 
cysteine active site and the E1 enzyme (Garg et al. 2020). However, the 
mechanism to transfer the ubiquitin chain to the target remains elusive. In 
order to understand whether the pro-proliferative effect of UBE2G1 
overexpression on cardiomyocytes was due to its catalytic activity, we 
substituted the cysteine residue to alanine in the catalytic loop, which had 
the effect of abolishing completely the pro-proliferative effect of this factor. 
Our data complement the previous report by Choi and colleagues showing 
that the substitution of the active cysteine by a serine was not significantly 
affecting K48-polyubiquitin chain synthesis (Choi et al. 2015), whereas the 
exchange between cysteine and alanine residue of UBE2G1 inhibited its 
activity. The exchange of cysteine to serine residue is a conservative 
replacement, while cysteine replaced by alanine impacts vigorously the 
intramolecular affinity of protein domains, possibly affecting the proper 
folding of the protein (Hizi et al. 1992). This explanation is consistent with 
the lack of any pro-proliferative effect by the mutant UBE2G1-CA protein in 
cardiac myocytes. Still, we do not exclude the possibility that the 
overexpression of UBE2G1-CA could compete with the endogenous 
protein, acting as a dominant-negative partner, therefore suppressing the 
downstream signalling and the consequent biological effect.

We showed that UBE2G1 is essential for cardiomyocyte cell cycle entry, 
as the depletion of this factor arrests the cells in the G1 phase and prevents 
cell cycle progression by FACS analysis. We reinforced this observation by 
presenting evidence that UBE2G1 inhibition abolished the pro-proliferative 
effects of miRNAs (miR-199a-3p, miR-590-3p, miR-302c, miR-373, and 
miR-1825) previously demonstrated to induce myocyte proliferation (Eulalio 
et al. 2012). Our data are consistent with the findings that UBE2G family 
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members, namely UBE2G1 and UBE2G2, control the degradation and 
ubiquitylation of the replication licensing factor CDT1 and Cyclin-
dependent kinase (Cdk) inhibitor p21, respectively. Origin licensing is the 
first committed step of DNA replication and its control is intimately 
coordinated with the mechanisms that govern cell cycle progression. In 
mammalian cells, small changes in CDT1 leads to catastrophic 
consequences of genome stability (Arentson et al. 2002; Tatsumi et al. 
2006; Blow and Gillespie 2008), suggesting that CDT1 regulation is strictly 
necessary. Moreover, the critical aspect of re-replication control in 
metazoans is ubiquitin-mediated, and CDT1 degradation during S phase is 
known to be controlled by different E3 ubiquitin ligase complexes (Abbas 
and Dutta 2011; Havens and Walter 2011; Petroski and Deshaies 2005).

As mentioned above, UBE2G1 is associated with CDT1 stability for 
modulating cell cycle progression, thus a logical step in our experiments 
was to demonstrate a direct (or indirect) interaction between UBE2G1 and 
the CRL1Skp2 complex. Indeed, this complex controls the degradation of 
CDT1, thus affecting the G1/S entry of myocytes in the cell cycle. In 
cultured cardiomyocytes with overexpression of UBE2G1 protein, we could 
not detect direct interaction of UBE2G1 and CDT1 protein by co-
immunoprecipitation, while we were able to confirm the CDT1 and CUL1 
interaction, as it was previously described by Li and colleagues (Li et al. 
2003). To explain these results, we have to consider that the identification 
of E2 conjugating enzyme partners is a major obstacle in studying E2 
functions, as they are known to interact with multiple E3 ligases through a 
relatively weak and transient interaction that leads to a speedy degradation 
of their substrates (Polge et al. 2015). Thus, it might be possible that the 
detection of a direct interaction between UBE2G1 and the CDT1 
degradation complex might have escaped our co-immunoprecipitation 
studies. Further investigations are needed to unravel the network of 
proteins responsible for the biological effect that we detect upon 
overexpression of UBE2G1. In recent work, an E2 thioester approach 
(E2~dID) has been developed to identify the substrates of UBE2C and its 
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partner E3 ligase (Bakos et al. 2018). This strategy can be pursued in our 
case, as well, by the creation of a mutant UBE2G1 able to covalently and 
permanently bind the interacting E3 enzyme without promoting the 
degradation of its substrates. In addition, through an immunoprecipitation 
assay, we also excluded the possible interaction between UBE2G1 and any 
of the E3 ligases identified in our screening as potential modulators of cell 
cycle progression. Another possible explanation for the apparent lack of 
direct interaction between UBE2G1 and an E3 ligase might reside on the 
unique feature of UBE2G1 and UBE2R1, which can synthesize K-48 
polyubiquitins without an E3 ligase (Choi et al. 2015). And the absence of 
evidence for a direct molecular interaction between UBE2G1 and any E3 
known ligase supports this possibility. 

UBE2G1 is involved in cell cycle regulation by controlling CDT1 and p21 
protein levels in response to UV irradiation (Shibata et al. 2011). Following 
this observation, we expanded the panel of cell cycle factors that might be 
affected by UBE2G1. We noticed that, upon the silencing of UBE2G1, the 
expression levels of cyclin D1 and cyclin E, the two factors that are required 
at the G1/S checkpoint (Resnitzky et al. 1994), were markedly reduced. 
Conversely, p27 expression was induced significantly at both 
transcriptional and protein levels. This result reinforces our hypothesis that 
UBE2G1 participates in the selective ubiquitylation of substrates involved in 
cell cycle regulation.

We further investigated the signalling cascades modulated by UBE2G1 
protein (upon overexpression and silencing) in cultured cardiomyocytes by 
evaluating the phosphorylation profile of 43 common kinases expressed in 
this cell type. We found that, in UBE2G1 overexpression condition, the 
GSK-3β, STAT3, and ERK1/2 pathways were affected. In particular, the 
upregulation of UBE2G1 induced inactivating phosphorylation of GSK-3β, a 
known inhibitor of cardiomyocyte replication (Lal et al. 2015; Singh et al. 
2018; Tong et al. 2002). Consistently, ERK1/2 activation is enhanced to 
mediate cell proliferation (Lorenz et al. 2009; Wang 2007). In the case of 
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STAT3, UBE2G1 protein functions through a non-canonical mechanism 
which has been involved in cell proliferation, survival, and the enhancement 
of transcriptional activity (Hazan-Halevy et al. 2010; Ouedraogo et al. 2016). 
Together, these evidence support the pleiotropy of targets regulated by the 
UBE2G1 enzyme, strengthening the indication that this factor acts on the 
cardiomyocyte cell cycle by modulating multiple targets and thus tuning a 
coordinated signalling network toward a proliferative response.  

In this view, we focused our attention on the biochemical cascades that 
we and others have demonstrated to drive cardiomyocyte proliferation, 
namely the Notch1 and Hippo pathways (Collesi et al. 2008; Torrini et al. 
2019). The ubiquitination cascade tightly controls the amplitude of both 
pathways in different manners (Kim and Jho 2018; Moretti and Brou 2013). 
For example, the E3 ligase ITCH targets and destabilizes the LATS1 kinase 
to suppress the downstream signalling, while the Notch1 intracellular 
domain (NICD) is the known substrate of the nuclear E3 ligase FBXW7, 
which ensures its fast recycling on target promoters and rapid degradation 
in physiological circumstances (Close et al. 2019; Salah et al. 2011). 
Moreover, recent data from our laboratory demonstrated that activated 
Notch1 half-life is extended by acetylation, a post-translational modification 
that competes with the ubiquitylation to enhance its transcriptional activity 
and sustain cardiomyocyte proliferation (Collesi et al. 2018). Of note, an E2 
conjugating enzyme involved in regulating these pathways has not been 
identified yet. 

Based on the above considerations, we asked whether UBE2G1 levels 
could affect the activity of these pathways. Our results showed that the 
silencing of UBE2G1 was paralleled by reduced amounts of NICD in 
transfected cells, while its overexpression increased the nuclear NICD 
protein level, subsequently sustaining the proliferative capability of cultured 
cardiac myocytes. These data were supported by transcriptional 
upregulation of Notch1 known target genes, such as Hes1 and Hey1 when 
UBE2G1 was overexpressed. In a similar experiment, we noticed an 
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interesting connection between UBE2G1 and YAP activity. The fractionation 
of transduced cardiomyocytes did not show a significant change in the 
nuclear levels of YAP affected by the shift in UBE2G1 levels. Consistently, 
we could not detect any significant difference in the expression of Ctgf and 
CyR61, two known YAP-responsive genes positively involved in cell 
proliferation. Conversely, in the case of UBE2G1 silencing, we observed a 
significant increase of atrial natriuretic factor (ANF), a hypertrophic marker. 
Our results are consistent with a previous report by Yang and colleagues, 
showing that the constitutive expression of YAP triggered cardiac 
hypertrophy and inhibited cell death both in vitro and in vivo through 
miR-206 overexpression. Similar to our results, these authors presented a 
significantly increased of Anf mRNA by miR-206 upregulation and YAP 
activation, which regulated the hypertrophy and survival of cardiomyocytes 
but did not exert any significant pro-proliferative effect (Yang et al. 2015). 
These data are relevant to our observation on the hypertrophic phenotype 
of cardiac myocytes when we treated cells with siUBE2G1 and miRNAs. 
We can argue that, in these conditions, UBE2G1 suppression impacts on 
the cytoskeletal structure of cardiomyocytes, which needs to be reshaped 
to a hypertrophic response. A similar observation of UBE2G1 modification 
affecting cardiac myocyte structure was reported by Haghikia and 
colleagues by showing that its silencing resulted in the loss of several 
sarcomeric proteins, including cardiac myosin heavy chain and troponin 
although the induction of hypertrophy was not reported (Haghikia et al. 
2010). 

To better clarify the impact of UBE2G1 overexpression on cardiomyocyte 
proliferation, we first tested the effect of this factor in vivo by evaluating the 
proliferative capacity of neonatal mouse hearts after the injection of AAV9-
UBE2G1, followed by EdU administration to measure the cell turnover. At 
seven days after the delivery of the AAV vector, we observed a significant 
increase in EdU incorporation, consistent with our in vitro data. We then 
wondered whether UBE2G1 overexpression could exert a therapeutic effect 
after myocardial infarction in adult mice. We found that a single 
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intracardially administration of AAV9-UBE2G1 significantly preserved the 
heart function of adult mice at 15 and 30 days after myocardial infarction, 
while the beneficial effect was not significant at 60 days. We attribute this 
lack of effect at longer times to a draft decrease of the transgene 
expression in the heart of injected mice. The loss of transgene expression 
in vivo is not a sporadic event with AAV vectors, since it was reported in 
several clinical trials to deliver the factor IX to hemophilic patients. In these 
cases, the drop of factor IX levels was a time-dependent event suggesting 
the transduced hepatocytes were removed gradually by the immune 
system (Manno et al. 2006; Nathwani et al. 2014). Although this event was 
barely mentioned in rodent, it is a feasible explanation for the drop of 
UBE2G1 expression after myocardial infarction, as the boost of the 
inflammation might provoke cell-mediated immunity targeting antigens of 
the AAV capsid, followed by the removal of transduced cells and decreased 
the beneficial effect (Frangogiannis 2014; Santos-Zas et al. 2019). Apart 
from preventive immunosuppression, some strategies can be conceived to 
avoid immune reactivity against AAV vectors. A widely investigated 
approach involves the modification of capsid immunogenic epitopes by 
random mutagenesis, also by including epitopes specifically activating 
suppressive T regulatory cells (Li et al. 2012). Another possibility harnesses 
the use of empty capsids as decoys to adsorb anti-AAV antibodies, 
although increasing the viral particle load may increase the cytotoxic T 
lymphocyte response (Mingozzi and High 2013). Notably, a recent study on 
chondrocyte cell line C28/I2 reported that circulating mRNA-UBE2G1 
affected the expression levels of pro-inflammatory cytokines such as IL-6, 
IL-1β and TNF-⍺ (Chen et al. 2020). Therefore, further studies appear 
required to understand the possible relation of UBE2G1 and the immune 
system in order to prevent the loss of AAV9-UBE2G1 transduced cells due 
to the clearance by the immune response. 

As mentioned earlier, ubiquitination plays irreplaceable roles in protein 
quality control as a priming system to dispose the proteins with abnormal 
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modifications (Pagan et al. 2013). Post-translational modifications by this 
system are faster and more efficient in response to environmental changes 
as it does not require the synthesis of molecules and can be reversed when 
the stimulus vanishes (Ashida et al. 2014). The versatility of ubiquitination 
makes it an attractive target for different fields of biomedical research 
although the lack of functional studies and fragmentary literature have 
restricted its applicative translation (Wertz and Wang 2019). 

Herein, we report for the first time the roles of the E2 conjugating enzyme 
UBE2G1 on cardiomyocyte proliferation both in vitro and in vivo. Our data 
reveal that this factor is capable of enhancing the replication of cardiac 
myocytes by modulating the levels of different cell cycle regulators. We also 
demonstrate a possible interaction of UBE2G1 with some pivotal signalling 
cascades driving cell proliferation, highlighting the multifaceted effect of 
this E2 conjugating enzyme on various cell functions. 

Further investigations require the identification of the E3 ligase partners 
(if any), of UBE2G1 in the heart and its ultimate substrates, in order to shed 
light on the actual molecular mechanisms that mediate the progression of 
cell cycle and enhance cardiomyocyte proliferation by this factor. Moreover, 
several experiments can be performed to better clarify the biological 
function of UBE2G1. These include: (i) to identify the impact of UBE2G1 on 
p27 stability as its silencing increased the half-life of this protein, thus the 
E3 ligase complexes that participate in this process can be assessed for 
the interaction; (ii) to validate the silencing effect of UBE2G1 on 
cardiomyocyte replication and hypertrophy in vivo; an AAV9-shUBE2G1 has 
already been generated for this experiment; (iii) to investigate the possible 
relation of UBE2G1 with different complexes that involve in DNA origin 
licensing beside CDT1, such as MCM, ORC and CDC.    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